Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
04/2009 | Recent  |  14: Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions April category listing, related patent applications 04/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
04/30/2009 > patent applications in patent subcategories. category listing, related patent applications

20090111734 - Compositions and methods for promoting hemostasis and other physiological activities: Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaiminate a site upon removal of previously... Agent: Wolf Greenfield & Sacks, P.C.

20090111732 - Gelling hydrophobic injectable polymer compositions: Biodegradable carriers synthesized from ricinoleic acid oligoesters and aliphatic molecules having at least one carboxylic acid and at least one hydroxy or carboxylic acid group that are liquids or pastes at temperatures below 37° C. and methods of making and using thereof are described herein. The polymers described herein significantly... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090111731 - Novel topical application agents against mimic and age-related wrinkles: R6 represents hydrogen or, when n is 1, also amino or together with R1 and the residue to which R6 and R1 are bound a 5- to 7-membered, saturated ring, as well as their physiologically acceptable salts are new. They can be manufactured according to common methods and processed to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090111733 - Par-4 related methods and compositions: Provided herein are methods and compositions for treating or preventing mood disorders and certain other mental disorders. Methods may comprise increasing PAR-4 levels or activity and/or the interaction between PAR-4 and the dopamine (D2) receptor... Agent: Foley Hoag, LLP Patent Group (w/huv Hmv)

20090111730 - Polypeptide protracting tags: Method for increasing (protracting) half-life of LGP analogs in plasma and novel derivatives of such peptides based on covalently linking them to a tetrazole moiety which acts as a carboxylic acid bioisostere.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090111735 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents: Novel compositions and formulations are disclosed that have use to mitigate or prevent physiologically deleterious side-effects and/or modulate the intracellular balance of oxidized and reduced thioredoxin (Trx) in patients with cancer who are receiving treatment with one or more chemotherapeutic agents. The compositions of matter are amino acid and peptide... Agent: Scott A. Whitaker, Senior Intellectual Property Counsel

20090111738 - Fibronectin polypeptides and methods of use: Described herein are fragments of fibronectin and variants thereof that bind growth factors. Compositions containing such a fragment of fibronectin are therefore useful in sequestering growth factors, and complexes containing both a FN fragment and a bound, active growth factor can be used to deliver growth factors to a patient... Agent: Fish & Richardson PC

20090111737 - Novel antibacterial agents: a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, pencillinase enzyme, cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate; Preferably, the ligands are selected from the beta lactam or glycopeptide class of antibacterial agents.... Agent: Theravance, Inc.

20090111736 - Orally-absorbed solid dose formulation for vancomycin: An orally bioavailable pharmaceutical composition comprises at least 40% (w/w) vancomycin; a permeation enhancer component comprising 0.1 to 10.0% (w/w) of a polyoxyethylene sorbitan fatty acid ester; and a particulate carrier onto which the permeation enhancer component is adsorbed.... Agent: Richard Aron Osman

20090111739 - Sugar chain added glp-1 peptide: The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at... Agent: Brinks Hofer Gilson & Lione

20090111740 - Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders: The present invention relates to the use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders. In particular, the invention relates to methods of treating patients suffering from cognitive disorders, in which the mode of administration of the drug comprises... Agent: Darby & Darby P.C.

20090111741 - Method for treating and/or preventing drug seeking behavior: A dynorphin-A analog can be used for treatment, inhibition, and/or prevention of cocaine seeking behavior, and or the drug seeking behavior for a cocaine derivative or other structurally related substance. The dynorphin-A analog can be a cyclic dynorphin-A analog having sufficient systemic stability that crosses the blood-brain barrier so as... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090111747 - Anti-diabetic or anti-hypertensive dietary supplement: An anti-diabetic or anti-hypertensive fish protein hydrolysate is provided, in which the fish is of the genus Salmo or Oncorhynchus, and wherein the fish protein is hydrolysed by a metalloendopeptidase obtainable from Bacillus amyloliquefaciens. Methods of making and methods for using such fish protein hydrolysates are also provided.... Agent: Smart & Biggar P.o. Box 2999, Station D

20090111743 - Cysteine-branched heparin-binding growth factor analogs: The present invention provides a heparin binding growth factor analog of any of formula I-VIII and methods and uses thereof.... Agent: Peacock Myers, P.C.

20090111749 - Delivery of active agents: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is... Agent: K&l Gates LLP

20090111748 - Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease: This invention pertains to the discovery that fibroblast growth factor 2 (FGF2) stimulates neurogenesis, induces migration of newborn cells into the striatum and cortex, is neuroprotective, and significantly extends the lifespan mammals suffering from neurodegenerative conditions (e.g., Huntington's disease, Parkinson's disease, etc.). In certain embodiments this invention provides a method... Agent: Goodwin Procter LLP Patent Administrator

20090111744 - Human growth gene and short stature gene region: Subject of the present invention is an isolated human nucleic acid molecule encoding polypeptides containing a homeobox domain of sixty amino acids having the amino acid sequence of SEQ ID NO: 1 and having regulating activity on human growth. Three novel genes residing within the about 500 kb short stature... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090111750 - Keratin derivatives and methods of making the same: Soluble keratin derivatives are disclosed. The soluble keratin derivatives may include a soluble keratin protein having at least one substituted chemical group at a lysine group, terminal amine group and/or hydroxyl amino acid group of a soluble keratin protein. Soluble keratin derivatives may be formed by succinylation or quaternisation, or... Agent: Holland & Hart, LLP

20090111751 - Method of removing a non-metallic protein inhibitor from a liquid pharmaceutical preparation: The invention relates to a method for removing a protein inhibitor from a liquid pharmaceutical preparation, said method comprising the steps of: (a) providing a sealed container comprising an initial liquid pharmaceutical preparation comprising (i) a protein belonging to the group of serine proteases/Vitamin K-dependent proteins and (ii) a non-metallic... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090111746 - Modulating toll-like receptor activity: This description provides methods and materials related to modulating Toll-like receptor activity. For example, methods and materials for increasing or decreasing the responsiveness of a TLR4 polypeptide are provided.... Agent: Fish & Richardson P.C.

20090111745 - Plad domain peptides with increased serum half life due to conjugation to domain antibodies: Drug fusions and conjugates that contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.... Agent: Mcdermott Will & Emery LLP

20090111752 - Stable formulation of modified glp-1: Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090111742 - Use of fgf-21 and thiazolidinedione for treating type 2 diabetes: A method for treating type 2 diabetes and metabolic syndrome comprising administering an effective amount of fibroblast growth factor 21 in combination with a thiazolidinedione.... Agent: Eli Lilly & Company

20090111753 - Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof: Nogo, MAG, and OMgp are myelin-derived proteins that bind to a neuronal Nogo-66 Receptor (NgR) to limit axonal regeneration after CNS injury. Nogo-A protein may play the most prominent role in vivo, perhaps because its action is mediated both by NgR and by other receptors. Here, we extend our previous... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090111754 - Selective inhibitors of nuclear factor kappab activation and uses thereof: The present invention provides cell permeable NF-κB inhibitors consist of a polypeptide derived from the p65 subunit of NF-κB and a protein transduction domain derived from antennapedia third helix sequence. The inhibitor suppressed NF-κB activation induced by TNF, LPS, IL-1, okadaic acid, PMA, H2O2 and cigarette smoke condensate. NF-κB-regulated reporter... Agent: Fulbright & Jaworski, L.L.P.

20090111755 - Methods for the use of inhibitors of antigen presentation by mhc class ii molecules: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.... Agent: Jones Day

20090111756 - Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.... Agent: Seattle Genetics, Inc.

20090111757 - Hcv protease inhibitors: r

20090111758 - Use of therapeutically useful peptides: The invention relates to preventing and treating endothelial dysfunction by using biologically active peptides and products containing them. In particular, the tripeptides Ile-Pro-Pro (IPP), Val-Pro-Pro (VPP) or mixtures, concentrates or other products containing them are used. A specific aspect of the present invention is to enhance the elasticity of blood... Agent: Nixon & Vanderhye, PC

20090111759 - Synergistic combination of glutamate-and gaba-gated chloride agonist pesticide and at least one vitamin e, niacin, or derivatives thereof: Presented are pesticidal compositions comprising at least one pesticide selected among Glutamate- or GABA-gated chloride channel agonist pesticides and at least one synergist which is selected among Vitamin E, Niacin and derivatives thereof. The combinations of these compounds show a synergistic effect allowing a composition to be prepared comprising a... Agent: Jacobson Holman PLLC

20090111760 - Macrolone compounds: e

20090111761 - Prostaglandin analog compositions and methods to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair. The present invention... Agent: Beverly W Lubit

20090111765 - Compositions and methods for immunostimulatory rna oligonucleotides: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IL-12-inducing activity to a single-stranded RNA oligonucleotide. The present invention also provides single-stranded RNA oligonucleotides, including antisense RNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of... Agent: Seed Intellectual Property Law Group PLLC

20090111763 - Loadable polymeric particles for bone augmentation and methods of preparing and using the same: Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles... Agent: Sutherland Asbill & Brennan LLP

20090111762 - Method of diagnosing and treating cancer using b-catenin splice variants: The invention relates to method of diagnosing and treating cancer, in particular β-catenin related cancers. The invention further relates to methods of identifying CTNNB1 related cancer CTNNB1 therapeutics.... Agent: Edwards Angell Palmer & Dodge LLP

20090111764 - Mitochondrial selection: Systems, methods, compositions and apparatus relating to genome, chromosome, and mitochondria selection are disclosed.... Agent: Searete LLC Clarence T. Tegreene

20090111767 - Modulation of insulin like growth factor i receptor expression: The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human... Agent: Morrison & Foerster LLP

20090111766 - Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases: Disclosed are recombinant adeno-associated viral (rAAV) vector compositions that are expressed in selected mammalian cells, such as pancreatic islets cells, and that encode one or more mammalian serpin or cytokine polypeptides having therapeutic efficacy in the amelioration, treatment and/or prevention of interleukin deficiencies, such as for example diabetes, and related... Agent: Haynes And Boone, LLPIPSection

20090111768 - Regulators of protein misfolding and neuroprotection and methods of use: Polynucleotide molecules and the proteins encoded by the molecules, diagnostic and treatment methods for neurological disorders characterized by protein aggregation are provided. Genes are described herein that affect the misfolding of, and subsequent aggregation of, aggregation-prone proteins such as alpha-synuclein and have implications for the diagnosis and treatment of neurological... Agent: King & Spalding

20090111769 - Antithrombotic compound: The present invention relates compounds of the formula I: oligosaccharide-spacer-GpIIb/IIIa antagonist I, wherein the oligosaccharide is a negatively charged pentasaccharide residue of the structure (I), the charge being compensated by positively charged counterions; the spacer is an essentially pharmacologically inactive linking residue of a length of 15-50 atoms; the GpIIb/IIIa... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090111771 - Inhibition of cathepsin k activity and the treatment and prevention of disease: The present invention provides a candidate compound that is suitable for use in methods of treating animals (preferably mammals) and in the preparation of a medicament, wherein the candidate compound down regulates Cathepsin K activity.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090111770 - Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate and use of calcium chelating agent and ophthalmologically compatible viscosity regulator: The invention relates to a pharmaceutical composition free from dexpanthenol, calcium ions and phosphate, comprising at least one calcium chelating agent and at least one opthalmologically compatible viscosity regulator and optionally one or more pharmaceutical excipients. The invention further relates to the use of a calcium chelating agent and an... Agent: Raymond J. Lillie Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart &

20090111772 - Formulation of quinazoline based egfr inhibitors containing a zinc binding moiety: The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their... Agent: Elmore Patent Law Group, PC

20090111773 - Compositions and methods of using lamellar bodies for modifying linear biological macromolecules: Compositions comprising therapeutically effective amounts of lamellar bodies for the modification of linear macromolecules are disclosed. These lamellar compositions are useful in the treatment of conditions or diseases characterized by a preponderance of heavy mucous secretions, such as otitis media, cystic fibrosis, bronchitis, sinusitis and nasal congestion. Methods of treating... Agent: Klauber & Jackson

20090111774 - Pmea lipid conjugates: The present invention relates to PMEA lipid conjugates and to methods of using the conjugates to treat diseases caused by viruses such as herpes, cytomegalovirus, varicella, paramyxovirus, polyoma virus, and human papillomavirus. Methods for making the PMEA lipid conjugates are also provided.... Agent: Wolf Greenfield & Sacks, P.C.

20090111775 - Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo: Novel molecular transporter compositions and their use for transporting bioactive substances into cells in living animals are disclosed. To afford in vivo delivery, the composition is covalently linked to the bioactive substance and the resultant composite structure is introduced into the subject. The transporter composition includes multiple guanidine moieties on... Agent: Teri G. Andrews Attorney At Law

20090111776 - Novel tetracycline derivatives as antibacterial agents: v

20090111778 - 2-keto-oxazoles as modulators of fatty acid amide hydrolase: Certain 2-keto-oxazole compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation,... Agent: Philip S. Johnson Johnson & Johnson

20090111777 - Jelly composition: It is intended to provide a composition having at least one effect among the following effects; a plurality of medicinal ingredients can be taken as one preparation and the convenience for patients is excellent; the drug compliance is excellent; the amount of jelly composition to be taken at a time... Agent: Birch Stewart Kolasch & Birch

20090111779 - Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea;... Agent: Frommer Lawrence & Haug

20090111785 - Combinations comprising antimuscarinic agents and corticosteroids: Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic... Agent: Hoxie & Associates LLC

20090111782 - Composition and methods relating to glucocorticoid receptor-alpha and peroxisome proliferator-activated receptors: Methods of treating a glucocorticoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering, in combination, a glucocorticoid receptor agonist and a PPAR agonist in therapeutically effective amounts. It is an aspect of the present invention that the amount of the glucocorticoid receptor... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090111780 - Compositions and methods for treatment of ear canal infection and inflammation: The present invention relates to compositions and methods for treatment of ear infections and inflammation. Specifically, the method involves administering to a patient a composition containing an antibacterial, an anti-inflammatory, and an anti-septic that is substantially free of pramoxine to treat the occurrence or negative effects of otic infection and... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090111783 - Dermatological compositions comprising hydroquinone, fluocinolone acetonide and tretinoin for treating the hyperpigmentation of pathological scars: Dermatological medicament compositions contain a combination of hydroquinone, fluocinolone acetonide and tretinoin and are useful for the treatment of the hyperpigmentation of pathological scars, namely, hypertrophic scars and keloidal scars.... Agent: Buchanan, Ingersoll & Rooney PC

20090111784 - Medication against breast cancer and related diseases: The present invention relates to novel uses of a steroid compound, which specifically binds to the androgen receptor (AR) but which is not metabolized by aromatase to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of... Agent: Griffin & Szipl, PC

20090111781 - Use of cymipristone type compounds in aids treatment: This invention refers to use of cymipristone type compounds of formula (I), salt or solvate thereof in preparation of medicament for treating AIDS. Cymipristone type compounds are a new type glucocorticoid receptor antagonist. Pharmacological test shows that cymipristone has anti-glucocorticoid activity and very strong affinity with glucocorticoid receptor. Test indicates... Agent: Scully Scott Murphy & Presser, PC

20090111786 - Compounds that prevent macrophage apoptosis and uses thereof: The present invention relates to microbial infection, and in particular, the reduction of apoptosis associated with microbial infection, the screening of Liver X Receptor agonist and/or Retinoid X Receptor agonist that reduce apoptosis, and the treatment and analysis of microbial infection in vivo. In one embodiment, the present invention relates... Agent: Medlen & Carroll

20090111787 - Polymer blends for drug delivery stent matrix with improved thermal stability: Various embodiments of the present invention generally relate to a polymer blend composition used for coating a medical device that exhibits improved thermal stability. The invention also encompasses implantable medical devices coated the aforementioned coating.... Agent: Squire, Sanders & Dempsey LLP

20090111788 - Antibiotic compositions of modified release and process of production thereof: Novel modified release pharmaceutical compositions wherein the composition comprises at least one antibiotic(s) preferably amoxicillin or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof either alone or in combination with other antibiotic(s) as active ingredient, with at least one release modifying agent(s) for controlling the... Agent: Ladas & Parry LLP

20090111789 - Chiral cis-imidazolines: v

20090111790 - Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes:

20090111791 - Soluble epoxide hydrolase inhibitors and methods of using same: Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.... Agent: Micheal P. Morris Boehringer Ingelheim Usa Corporation

20090111792 - Injectable capsaicin with tricyclic antidepressant adjunctive agent: Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a tricyclic antidepressant.... Agent: Davidson, Davidson & Kappel, LLC

20090111793 - Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20090111794 - Aryl-substituted bridged or fused diamines as modulators of leukotriene a4 hydrolase: Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory... Agent: Philip S. Johnson Johnson & Johnson

20090111795 - Multimers of heterocyclic compounds and their use: A compound of formula (I): M-L-M, wherein L is a linker and each M is independently a group of formula (II): is useful in therapy, e.g. of respiratory diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090111796 - 7-membered ring compound and method of production and pharmaceutical application thereof: c

20090111797 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090111798 - 5,6-dihydro-1h-pyridin-2-one compounds: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Connolly Bove Lodge & Hutz LLP

20090111799 - Anti-infective agents against intracellular pathogens: e

20090111800 - Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia,... Agent: Eli Lilly & Company

20090111802 - Cyclocarbamate derivatives as progesterone receptor modulators: wherein R1 and R2 are independent substituents or are fused to form spirocyclic rings; R3, RC, and R4 are as defined herein; and R5 is a substituted benzene ring or a substituted five or six membered heterocyclic ring having in its backbone 1, 2, or 3 heteroatoms including O, S,... Agent: Howson & Howson LLP / Wyeth

20090111801 - Substituted pyrazinone derivatives for use as a medicine: The present invention concerns substituted pyrazinone derivatives according to the general Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1, having selective α2C-adrenoceptor antagonist activity.... Agent: Woodcock Washburn LLP

20090111803 - Compounds for the treatment of inflammatory disorders: e

20090111804 - Arylindenopyrimidines and their use as adenosine a2a: This invention relates to novel arylindenopyrimidines A, B, and C, and their therapeutic and prophylactic uses. Disorders treated and/or prevented using these compounds include Parkinson's Disease.... Agent: Philip S. Johnson Johnson & Johnson

20090111805 - Bicyclic heteroaromatic derivatives useful as anticancer agents: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, V, W, R4, R5, R6, R7, and ring B are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I and to pharmaceutical compositions for treating... Agent: Pfizer Inc

20090111806 - Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof: are useful as inhibitors of HIF prolyl hydroxylases where the definitions of the variables are provided herein.... Agent: Amgen Inc.

20090111807 - Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity: An object of the present invention is to synthesize a novel 1,2,3,4-tetrahydroquinoxaline derivative represented by formula (1) and to find a pharmacological action of the derivative. In the formula, the R1 represents a halogen, an alkyl, cycloalkyl, aryl or heterocyclic group, or the like; p represents 0 to 5; R2... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090111809 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention discloses novel compounds of Formula I: (I) having 11-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes,... Agent: Eli Lilly & Company

20090111808 - Novel histamine h3-receptor ligands and their therapeutic applications: The present patent application concerns compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated nitrogen-containing ring; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.... Agent: Stites & Harbison PLLC

20090111810 - Substituted pyrimidine-5-carboxamide and 5-carboxylic ester kinase inhibitors: e

20090111811 - 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090111813 - Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders: The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly... Agent: Knobbe Martens Olson & Bear LLP

20090111812 - Methods for treating inflammatory disorders: The present invention relates generally to the fields of molecular biology. More particularly, it concerns materials and methods for the treatment of nitric oxide and cytokind mediated disorders. In a preferred embodiment, PDMP may be used to inhibit the expression of iNOS and pro-inflammatory cytokines such as TNFα and IL1β.... Agent: Fulbright & Jaworski L.L.P.

20090111814 - Feminine anti-itch gel: The present invention provides a substantially clear gel designed to reduce itching discomfort when applied to the vulvar tissue. The gel includes at least one anesthetic, protectant, emulsifier, and pH modifier, such as a base. The gel has a pH adapted to vulvar use and may be applied to the... Agent: Evan Law Group LLC

20090111815 - Carboxamide compound and use of the same: [wherein Q represents a nitrogen-containing 6-membered aromatic heterocyclic group optionally fused with a benzene ring, two or more ring constitutional atoms of the heterocyclic group are a nitrogen atom, and the heterocyclic group may be substituted with at least one group selected from the group consisting of a C1-C3 alkyl... Agent: Birch Stewart Kolasch & Birch

20090111816 - Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors: Polycyclic aryl and polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl catalytic activity are also disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20090111817 - Combinations of eszopiclone and an antidepressant: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20090111818 - Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20090111822 - 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090111824 - Amide linked heteroaromatic derivatives as modulators of mglur5: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090111821 - Amino 1,2,4-triazole derivatives as modulators of mglur5: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090111823 - Aminopyridine derivatives as modulators of mglur5: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090111820 - Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090111819 - New pyridazin-3(2h)-one derivatives: e

20090111825 - Thiophene 1,2,4-triazole derivatives as modulators of mglur5: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090111826 - Use of ranolazine for the treatment of cardiovascular diseases: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.... Agent: Cv Therapeutics, Inc.

20090111827 - Arylindenopyrimidines compound and use as an adenosine a2a receptor antagonists: This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease.... Agent: Philip S. Johnson Johnson & Johnson

20090111828 - L-alanine derivatives: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases... Agent: Astrazeneca R&d Boston

20090111829 - Aripiprazole salts: The present invention provides for new salts of aripiprazole of the general formula (II) formed with dibasic organic acids, camphorsulfonic acid, phosphoric acid, and processes for their preparation. Further objects of the present invention are pharmaceutical compositions containing said new aripiprazole salts. Aripiprazole salts according to present invention can be... Agent: K.f. Ross P.C.

20090111830 - Substituted isoindolones and their use as metabotropic glutamate receptor potentiators: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090111831 - Pharmaceutical compositions: Disclosed herein are novel compositions useful for the treatment of androgen dependant diseases.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090111832 - Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to imidazolidinone compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of... Agent: Merck And Co., Inc

20090111833 - Injectable meclizine formulations and methods: Methods of treating or preventing a vertigo, nausea, or vomiting condition comprising injecting a subject with a pharmaceutically acceptable formulation consisting essentially of an effective amount of meclizine or a pharmaceutically acceptable salt thereof, a chemically modified cyclodextrin, and an aqueous carrier medium having a pH between about 2 and... Agent: Brinks, Hofer, Gilson & Lione

20090111834 - Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof: The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate)... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090111835 - Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence,... Agent: Sughrue Mion, PLLC

20090111836 - Angular pyranocoumarins, process for preparation and uses thereof: The present invention relates to compounds, compositions for use in reversing multidrug resistance in cancer cells, process for the preparation thereof and their uses in treating cancers. More particularly, the present invention relates to 3′,4′-aromatic acyloxy substituted 7,8-pyranocoumarins compounds for use in reversing P-glycoprotein overexpression mediated multidrug resistance in cancer... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090111837 - Use of pde7 inhibitors for the treatment of neuropathic pain: The present invention relates to the use of a phosphodiesterase 7 (PDE7) inhibitor in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an inhibitor of PDE7.... Agent: Pfizer Inc.

20090111838 - 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors: e

20090111839 - Process for preparing amorphous rosuvastatin calcium of impurities: A pure amorphous form of rosuvastatin calcium substantially free from alkali metal impurities is disclosed. A process of preparing a pure amorphous form of rosuvastatin calcium is disclosed, which comprises hydrolysis of C1-C5 alkyl esters of rosuvastatin, preferably tert-butyl ester of rosuvastatin, with an organic nitrogen base, e.g. guanidines, amidines,... Agent: Novartis Corporate Intellectual Property

20090111840 - Heterocyclic spiro-compounds as aldosterone synthase inhibitors: The patent application relates to new heterocyclic compounds of the general formula (I) in which R, R1, R2, W, X, Y, Z and n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090111841 - Novel 3,9-diaza-spiro[5,5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: e

20090111842 - Spirocyclic cyclohexane compounds with analgesic activity:

20090111844 - Combination analgesic employing opioid and neutral antagonist: A non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects, and insufficient to block substantial central effects, of the opioid agonist in the subject. Such formulations, and methods... Agent: Bromberg & Sunstein LLP

20090111843 - Therapeutic or prophylactic agent for functional bowel disorder: A therapeutic or prophylactic agent for functional bowel disorders comprising as an effective ingredient a morphinan derivative having a nitrogen-containing cyclic group or a pharmaceutically acceptable acid addition salt thereof is disclosed. The therapeutic or prophylactic agent for functional bowel disorders comprises as an effective ingredient a morphinan derivative or... Agent: Birch Stewart Kolasch & Birch

20090111845 - Hydrated crystalline esters of camptothecin: Hydrated crystalline camptothecin esters, such as crystalline aliphatic ester hydrates of camptothecin, pharmaceutical compositions containing crystalline aliphatic ester hydrates of camptothecin, methods of treating a cancer or malignant tumor using the crystalline camptothecin ester hydrates and methods of making the same are described.... Agent: Kilyk & Bowersox, P.l.l.c.

20090111846 - Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders: Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.... Agent: Knobbe Martens Olson & Bear LLP

20090111847 - Preparation method and use of compounds having high insecticidal activities: The present invention discloses a kind of nitromethylene derivatives as well as their preparation method and their uses. The insecticidal activity tests show that the nitromethylene derivatives of the present invention not only show high insecticidal activities against insects with piercing-sucking type or scratching type mouthparts, such as aphid, leafhopper,... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090111848 - Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates: The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (I) wherein R, R1, X and Y have different meanings, and pharmaceutically acceptable salts thereof. Compounds of formula (I) are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation. The... Agent: Birch Stewart Kolasch & Birch

20090111849 - Crystalline salt of montelukast: Cyclopropylamine salt of montelukast in crystalline form and its use for the preparation of highly pure amorphous montelukast sodium.... Agent: Intellectual Property / Technology Law

20090111850 - Amino-substituted ethylamino beta2 adrenergic receptor agonists: The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20090111851 - Antimicrobial quinolones, their compositions and uses: e

20090111852 - Carboxamide compound and use of the same:

20090111853 - Fexofenadine polymorphs and process for the preparation thereof: The invention provides novel crystalline forms of fexofenadine hydrochloride, a process for the preparation of the novel forms and of the known form A, and their use in therapy.... Agent: Young & Thompson

20090111854 - 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090111855 - Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators: methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to... Agent: Philip S. Johnson Johnson & Johnson

20090111856 - Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation: The present invention relates to a stable sterilized parenteral formulation comprising an acid susceptible proton pump inhibitor. The formulation, a solid formulation comprising the acid susceptible proton pump inhibitor and optionally pharmaceutically acceptable excipients, has been sterilized in its final container by ionizing radiation. The container may consist of several... Agent: White & Case LLP Patent Department

20090111857 - 1,2,4-triazole ether derivatives as modulators of mglur5: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090111858 - Novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production: The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with β-amyloid peptide.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090111859 - Substituted biphenyl gpr40 modulators: e

20090111860 - Sulfonamide compounds useful as adg receptor modulators: The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as... Agent: Astrazeneca R&d Boston

20090111861 - Phthalamide derivative, agricultural or horticultural pesticide, and use of the pesticide: Disclosed is a phthalamide derivative represented by the general formula (I) or a salt thereof, which shows an excellent controlling effect for use as an agricultural or horticultural insecticide alone or in combination with other agricultural or horticultural insecticide, acaricide, nematicide, fungicide, herbicide, plant growth regulator, biopesticide or the like.... Agent: Manelli Denison & Selter

20090111862 - Compound: wherein each T is independently selected from H, hydrocarbyl, —F—R, and a bond with one of D, E, P or Q, or together with one of P and Q forms a ring; Z is a suitable atom the valency of which is m; D, E and F are each independently... Agent: Frommer Lawrence & Haug

20090111863 - Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of β-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.... Agent: Proteotech, Inc.

20090111864 - Diarylhydantoin compounds: The present invention relates to diarylhydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.... Agent: Venable LLP

20090111865 - Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof: e

20090111866 - Novel compounds:

20090111867 - Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to... Agent: Wyeth/finnegan Henderson, LLP

20090111868 - Use of rottlerin and its derivatives as activators of bk channel for therapy of hypertension and related disorders: The present invention provides compositions and methods for regulating the BK channel using rottlerin and derivatives thereof. In particular, the present invention provides pharmaceutical compositions for use in treating or preventing BK channel medicated disorders including hypertension and various hyperexcitability disorders. Also provided are compositions and methods for use in... Agent: Kevin C. Hooper Bryan Cave LLP

20090111869 - Benzoquinone ansamycins: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer... Agent: Morrison & Foerster LLP

20090111870 - Angelicae sinensis extracts useful for treatment of cancers: An acetone extract, chloroform extract or hexane extract of Angelicae sinensis and/or the active components purified therefrom, such as n-butylidenephthalide, are administered alone or in combination with one or more chemotherapy drugs and are effective in treating cancers.... Agent: Panitch Schwarze Belisario & Nadel LLP

20090111871 - Felbamate with improved bulk density: A synthesis and purification of felbamate, an anticonvulsant, are provided. The product of the synthesis and purification is with high untapped and tapped bulk densities, which increase ease of handling and suitability for use in pharmaceutical formulations. The felbamate may be incorporated into pharmaceutical compositions that can be administered orally... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090111872 - Stabilized pediatric suspension of carisbamate: The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HPMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form.... Agent: Philip S. Johnson Johnson & Johnson

20090111873 - Novel zeta-cypermethrin composition: The present invention is directed to an insecticidal composition comprising zeta-cypermethrin: a) prepared by an epimerization process, and b) containing a residual amount of an epimerization catalyst, and glycerine, wherein the zeta-cypermethrin is present in an insecticidally effective amount and to methods of using the composition.... Agent: Patent Administrator Fmc Corporation

20090111874 - Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof: The present invention relates to novel phenyl-N-acyl derivatives of biogenic amines and amino acids of general formula (I) as cyclooxynease inhibitors, possessing analgetic and anti-inflammatory properties and devoid of side effects in particular ulcerogeneity and pro-spasmodic actions, as well as capability to potentiate effect of other analgetics, and possessing in... Agent: Banner & Witcoff, Ltd.

20090111875 - Skin care compositions: Provided are compositions which are suitable for topical application to mammalian skin for cleansing and anti-microbial properties. In one embodiment, the compositions include a glyceryl monoazelate monolaurate ester. It is postulated that bacteria on or in the skin may cleave the ester linkage of a compound according to the present... Agent: Christopher J. Whewell Western Patent Group

20090111876 - Extracts from chlorella: This invention relates to an extract of Chlorella sorokiniana, which contains myristic acid, palmitic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, and stearic acid. Also related is use of this extract to treat diabetes, obesity, and dyslipidaemia.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090111877 - Methods for enhancing the quality of life of a senior animal: Methods for enhancing the quality of life of a senior or super senior animal by feeding the animal a composition comprising at least one omega-3 polyunsaturated fatty acid and various combinations of amino acids, minerals, and antioxidants in amounts effective to enhance alertness, improve vitality, protect cartilage, maintain muscle mass,... Agent: Colgate-palmolive Company

20090111878 - Teeth whitening material and teeth whitening method: The present invention relates to a tooth bleaching material containing peroxyglutaric acid and/or peroxypolyacrylic acid as a bleaching ingredient, as well as a method of bleaching teeth which include the step of applying the tooth bleaching material in the form of a dilute solution or without dilution onto surfaces of... Agent: Antonelli, Terry, Stout & Kraus, LLP

20090111879 - Inhibitors of alpha4 mediated cell adhesion: The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.... Agent: Birch Stewart Kolasch & Birch

20090111880 - Prostaglandin analog compositions and methods to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111882 - Prostaglandin analog compositions and methods to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111884 - Prostaglandin analog compositions and methods to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111886 - Prostaglandin analog compositions and methods to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111888 - Prostaglandin analog compositions and methods to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111890 - Prostaglandin analog compositions and methods to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111881 - Prostaglandin analog compositions to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111883 - Prostaglandin analog compositions to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111885 - Prostaglandin analog compositions to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111887 - Prostaglandin analog compositions to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111889 - Prostaglandin analog compositions to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111891 - Prostaglandin analog compositions to treat epithelial-related conditions: The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.... Agent: Beverly W Lubit

20090111892 - Rasagiline orally disintegrating compositions: This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant,... Agent: Cooper & Dunham, LLP

20090111893 - Method of lowering blood glucose and method of preventing or treating blood glucose and method of preventing or treating diabetes and obesity: i

20090111894 - Method of preventing microbial growth: There is provided a method of preventing microbial growth in an article, such as a consumer product or packaging material, whereby said article is treated with an effective amount of hydroxyacetaldehyde.... Agent: Unilever Patent Group

20090111895 - Enhanced dialdehyde disinfectant and sterilization formulations: High-level disinfectant formulations and sporicidal formulations suitable for use as chemical disinfection and sterilization mediums comprising a dialdehyde, a carboxylate salt in amount of from about 3 weight percent to about 20 weight percent, and the balance water. The formulations are useful for disinfecting and sterilizing medical instruments and medical... Agent: K&l Gates LLP

20090111896 - Use of hydrocarbon fluids in seed treatment: Treatment of seeds with hydrocarbon fluids improve germination under adverse conditions.... Agent: Exxonmobil Chemical Company

  
04/23/2009 > patent applications in patent subcategories. category listing, related patent applications

20090105119 - Asparagine-10-substituted nonadepsipeptides: The invention relates to nonadepsipeptides and methods for their preparation, as well as to their use for manufacturing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.... Agent: Morrison & Foerster LLP

20090105120 - Method for preparing tryptophan rich peptides: e

20090105115 - Polyamides for nucleic acid delivery: The present invention provides a new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications. The present invention also provides a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response. Complexes according... Agent: Dinsmore & Shohl, LLP

20090105116 - Polypeptide ligands containing linkers: There is provided herein a multivalent binding molecule and uses thereof. The molecule is useful in binding a target under certain conditions and releasing it under other conditions. The molecule has the general formula (1) of BM1-L-(BM2)n (1) wherein, BM1 is a binding moiety 1 having an affinity for site... Agent: Margaret Mckay National Research Council Of Canada

20090105118 - Preparation and applications of novel complexes made by gamma-polyglutamic acid and cisplatin: A series of complexes made by γ-polyglutamic acid (γ-PGA) and cisplatin, their preparation and applications in biomedical field, specifically in cancer treatment. The complexes may be made by binding free cisplatin on small molecule γ-PGA through the reaction between carboxylic group of γ-PGA and Cl of cisplatin. The complexes show... Agent: Butzel LongIPDocketing Dept

20090105117 - Stem cells and lim mineralization proteins: Methods of changing a phenotype of a cell are provided. The methods comprise increasing an amount of an amino acid sequence which is at least 70% identical to an amino acid sequence encoding an LMP protein or a fragment thereof in a cell. The cells may be contacted by either... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090105121 - Insulin derivative: The present invention relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090105124 - Heterocyclic modulators of tgr5: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of TGR5 activity in a human or animal subject are also provided for the treatment diseases mediated by TGR5.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20090105123 - Methods for the treatment of muscle loss: The invention provides methods for treating muscle loss in an individual. In one embodiment, the invention includes administering to an individual an effective amount of a branched chain amino acid (BCAA), a BCAA precursor, a BCAA metabolite, a BCAA-rich protein, a protein manipulated to enrich the BCAA content or any... Agent: Nestle Healthcare Nutrition

20090105125 - Methods of treating fatty liver disease: The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090105122 - Selective neuropeptide y2 receptor agonists: This invention provides peptides that act as selective NPY2 receptor agonists in vitro and are efficacious in vivo to reduce food intake. The invention is a peptide selected from a specific group of derivatized NPY-related peptides, or functional equivalents thereof. The invention is also directed to a method of treating... Agent: Barbara A. Shimei Director, Patents & Licensing

20090105127 - Methods for stabilizing corneal tissue: Methods of stabilizing collagen fibrils in a cornea are disclosed. The stabilization may be effected by treating the cornea with a protein that crosslinks collagen fibrils, such as decorin. The stablization methods include treatment of corneas before, during, or after a surgical procedure, treatment of keratectasia, and treatment of keratoconus.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090105126 - Methods of treating pulmonary disorders using liposomal vancomycin formulations: The present disclosure relates in part to methods of treating and prevention of pulmonary disorders in a subject in need thereof comprising administering to the subject a liposomal vancomycin compositions having low lipid to drug ratios and high concentration of vancomycin.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090105128 - Cannabinoid receptor targeted agent: e

20090105129 - Combination therapy: The present invention relates generally to methods for inducing, promoting or otherwise facilitating pain relief. More particularly, the present invention relates to a synergistic combination of a selective inhibitor of the neuronal norepinephrine transporter and an analgesic agent in the therapeutic management of vertebrate animals, including humans, for producing analgesia... Agent: Scully Scott Murphy & Presser, PC

20090105130 - Depsipeptide-containing injection solution: e

20090105132 - Method for enchancing cyclodextrin complexation: The present invention is directed to a method for complexing a cyclodextrin with a cyclosporin, according to which method the complexation is carried out at a temperature of the most 15° C.... Agent: Birch Stewart Kolasch & Birch

20090105131 - Use of poly-alpha2,8-sialic acid mimetic peptides to modulate ncam functions: The invention relates to the use of a peptide consisting of 5 to 30 amino acid residues, preferably 9 to 15, most preferably about 12 amino acid residues, said peptide comprising a B epitope of a poly-α2,8 sialic acid attached to NCAM, which is recognized by an anti-poly-α2,8 sialic acid... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090105140 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090105134 - C-terminally pegylated growth hormones: Conjugated growth hormones of the structure (I) are provided together with methods for manufacturing said conjugates. The conjugates are useful in therapy.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090105148 - Compositions and methods for treating myocardial infarction: The invention features compositions and methods that are useful for preventing or treating a cardiac disease or for promoting cardiac health following a myocardial infarction. The invention further features compositions and methods for promoting angiogenesis, cell proliferation, and/or decreasing apoptosis in muscle tissue, such as cardiac tissue. The invention provides... Agent: Edwards Angell Palmer & Dodge LLP

20090105147 - Deuterated etravirine: This disclosure relates to novel di-aryl-pyrimidine (DAPY) compounds and pharmaceutically acceptable salts thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a non-nucleoside reverse transcriptase inhibitor (NNRTI).... Agent: Fish & Richardson P.C.

20090105133 - Gamma-delta t cell receptors: The present invention provides gamma-delta T cell receptors (γδTCRs) with an introduced disulfide interchain bond. Such proteins, and cells expressing of such proteins on the surface thereof, have value in methods for distinguishing between cell populations by the TCR ligand they present, and in the treatment of diseases.... Agent: Banner & Witcoff, Ltd.

20090105143 - Hiv fusion inhibitor peptides with improved biological properties: Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide... Agent: Jones Day

20090105141 - Intraventricular protein delivery for amyotrophic lateral sclerosis: Amyotrophic Lateral Sclerosis can be successfully treated using intraventricular delivery of a neurotrophic growth factor, IGF-1. The administration can be performed slowly to achieve maximum effect. Effects are seen on both sides of the blood-brain barrier, making this a delivery means for Amyotrophic Lateral Sclerosis which affects both brain and... Agent: Genzyme Corporation Legal Department

20090105145 - Method of diagnosing and treating colon cancer: The invention provides a method of diagnosing carcinoma in a patient, the method comprising providing a sample of colorectal cells from a human patient and analyzing the sample for CXCL12 hypermethylation.... Agent: Quarles & Brady LLP

20090105138 - Methods for treating immune mediated neurological diseases: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, Immune complexed IgG to IgG FγR binding, and immune complexed IgG mC1q (membrane C1q) or soluble C1q binding. Such compounds... Agent: Fish & Richardson P.C.

20090105136 - Npy y2 agonist for use as therapeutic agent for disease accompanied by diarrhea: An NPY Y2 agonist is used as a therapeutic agent for a disease accompanied by diarrhea. A compound capable of treating the disease can be evaluated and screened by examining the compound on the targeting to an NPY Y2 receptor. An agent capable of inhibiting the diarrhea by a novel... Agent: Merck And Co., Inc

20090105144 - One-component bone cement pastes and methods for curing them:

20090105146 - Proteins, nucleic acids and medicaments: The invention provides TGF-β3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-β3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-β3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length... Agent: Goodwin Procter LLP Patent Administrator

20090105137 - Recombinant bone morphogenetic protein heterodimers, compositions and methods of use: The present invention relates to methods for producing recombinant heterodimeric BMP proteins useful in the field of treating bone defects, healing bone injury and in wound healing in general. The invention also relates to the recombinant heterodimers and compositions containing them.... Agent: Wyeth/finnegan Henderson, LLP

20090105139 - Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease: Soluble epidermal growth factor receptors 2 and 3 (HER2 and HER3) splice variant proteins with HER2 and HER3 antagonist activity and anti-proliferative properties, as well as the corresponding nucleic acids, are provided for treatment of proliferative diseases, in particular cancer. Also provided are compositions and methods for inducing expression of... Agent: King & Spalding LLP

20090105135 - Therapeutic agent for cancer: The present invention provides a cancer therapeutic agent containing as an active ingredient a substance, particularly CRM197 which inhibits the binding of HB-EGF to EGF receptor by binding to HB-EGF, wherein a cancer is selected from the group consisting of a bladder cancer, a colon cancer or peritoneal metastatic cancers... Agent: Fitch, Even, Tabin & Flannery

20090105142 - Treatment with kallikrein inhibitors: Methods, kits and compositions are disclosed that include a non-naturally occurring kallikrein inhibitor and an optional additional gout therapeutic for the treatment of gout, such as acute gout.... Agent: Lowrie, Lando & Anastasi, LLP

20090105149 - Compounds comprising lpa: The present invention relates to new peptide compounds capable of binding to fibroblast growth factor receptor (FGFR), said compounds comprising two individual amino acid sequences, wherein at least one of the two amino acid sequences is capable of binding to FGFR. The invention discloses the amino acid sequences of the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090105151 - Amphipathic alpha-helical peptide compositions as antiviral agents: The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090105150 - Angiotensin derivatives: An angiotensin derivative comprising at least one angiotensin peptide moiety coupled to a peptide carrier-binding moiety which can be used for therapy and prophylaxis of conditions associated with the renin activated angiotensin system.... Agent: Bacon & Thomas, PLLC

20090105152 - Metastin derivatives and use thereof: The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotrophic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of... Agent: Edwards Angell Palmer & Dodge LLP

20090105154 - Composition for prevention or treatment of gastrointestinal damage: e

20090105153 - Gonadotropin releasing hormone antagonists: Antagonistic peptides of GnRH having improved water solubility are disclosed. These peptides are capable of suppressing serum testosterone levels in vivo to chemical castration levels of ≦0.5 ng/ml. Stable, filter sterilizable, non-gelling solutions containing the GnRH antagonists at least at levels typically used in sustained release formulations also are disclosed,... Agent: Nanda P.b.a. Kumar Reed Smith LLP

20090105155 - Truncated lhrh formulations: The present invention provides a peptide useful for raising an antiLHRH response in an animal. The peptide comprises a first and second region, the first region consisting of a sequence of less than 60 amino acids which comprises at least one T helper cell epitope and the second region consisting... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090105156 - Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides: The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides.... Agent: Ropes & Gray LLP

20090105159 - Neuroprotective compounds and uses thereof: The present invention relates to a neuroprotective compound consisting of the amino acid sequence DLHW.... Agent: Fulbright & Jaworski L.L.P.

20090105158 - Peptide substance revealing a stress protective effect, pharmaceutical composition on its base, and the method of its application: The invention is related to the medicinal means of prevention and treatment for functional or stress induced disorders, which occur as a result of extreme impacts, and may be used as a medication revealing a stress protective effect. There is proposed a peptide glutamyl-aspartyl-glycine with general formula H-Glu-Asp-Gly-OH sequence 1... Agent: Leydig Voit & Mayer, Ltd

20090105157 - Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application: The invention is related to the medicinal means of treatment of diseases, traumas, as well as consequences of traumas of the central nervous system, and can be also used as a means of stimulating neurons regeneration. There is proposed a peptide glutamyl-aspartyl-arginine with general formula H-GIu-Asp-Arg-OH sequence 1 [SEQ ID... Agent: Leydig Voit & Mayer, Ltd

20090105160 - Pharmaceutical composition, package and method for rapidly reducing the uric acid in blood: The present invention relates to a pharmaceutical composition for rapidly reducing the uric acid level in blood in a subject, which comprises anserine in an amount of greater than 50 mg to about 600 mg. The present invention further relates to a package comprising the pharmaceutical composition comprising anserine, and... Agent: Ladas & Parry LLP

20090105161 - D-mannose contraceptives: The present invention concerns the use of D-mannose to prevent or inhibit uniting of sperm and egg/zygote in the conception process, both for specific target animals as well as general animal populations. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will... Agent: Venable LLP

20090105162 - Substituted fused heterocyclic c-glycosides: This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.... Agent: Philip S. Johnson Johnson & Johnson

20090105163 - Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy: The present invention relates to novel compounds represented by the structure I and pharmaceutical preparations thereof for the treatment of inflammatory diseases in humans and animals.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090105165 - Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides: This invention relates to substituted benzimidazole-O-glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.... Agent: Philip S. Johnson Johnson & Johnson

20090105164 - Substituted indole-o-glucosides: Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090105166 - Novel lapachone compounds and methods of use thereof: The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as β-lapachone... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20090105167 - Predicting responsiveness to cancer therapeutics: The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including salvage agents, to treat cancers such as ovarian cancer. The invention also provides... Agent: Michael Best & Friedrich LLP

20090105168 - Use of hdac and/or dnmt inhibitors for treatment of ischemic injury: The present invention provides methods of ameliorating or reducing the extent of ischemic injury, reperfusion injury, and myocardial infarction, by administering an inhibitor of histone deacetylase enzyme (HDAC) or an inhibitor of DNA methyltransferase enzyme (DNMT).... Agent: Pearl Cohen Zedek Latzer, LLP

20090105169 - Allele-specific silencing of disease genes: The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules.... Agent: Viksnins Harris & Padys Pllp

20090105179 - Drug carriers: Compositions that can include a cationic polymeric carrier, targeting agent, and therapeutic agent are disclosed herein. The therapeutic agent may have a therapeutic activity such as inhibiting fibrosis within a target organ or tissue or inhibiting the growth of a cancer cell.... Agent: Knobbe Martens Olson & Bear LLP

20090105180 - Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or... Agent: Morris Manning Martin LLP

20090105175 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of... Agent: King & Spalding

20090105176 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of... Agent: King & Spalding

20090105171 - Methods for regenerating and repairing damaged tissues using adrenomedullin: [Means for Solving the Problems] To solve the above problems, the present inventors administered adrenomedullin (hereinafter indicated as AM) or physiological saline to C57BL/6 mice, and counted the numbers of mononuclear cells and Sca-1-positive cells in the blood. The result showed that AM increased the numbers of mononuclear cells and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090105177 - Modulation of diacylglycerol acyltransferase 1 expression: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 1. Methods of using these compounds for modulation of diacylglycerol acyltransferase 1 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol... Agent: Mcdermott Will & Emery

20090105181 - Modulation of sodium channels by nicotinamide adenine dinucleotide: The present invention relates to the use of oxidized nicotinamide adenine dinucleotide (NAD+) or of its reduced form, NADH, as sodium channel modulators. The present invention also relates to the use of compositions containing NAD+ or NADH to treat conditions associated with sodium channel current, such as arrhythmia. NAD+ is... Agent: Blank Rome LLP

20090105170 - Multiple heat shock elements: A DNA molecule is provided which comprises at least 2 consensus sequences, each consensus sequence consisting of 3 pentameric units, said pentameric units having a sequence XGAAY or an inverse sequence Y′TTCX′, X being selected from the group consisting of A, T, G, and C, and Y of at least... Agent: Fulbright & Jaworski L.L.P.

20090105174 - Nucleic acids hybridizable to micro rna and precursors thereof: Methods and compositions relating to nucleic acids targeting certain miRNA molecules are disclosed. The nucleic acids are useful in methods of increasing nuclear concentration of FKHR protein, decreasing cell viability, and treating cancer.... Agent: Amgen Inc. Law Department

20090105183 - Pharmaceutical composition containing decoy and method of using the same: A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1... Agent: Foley And Lardner LLP Suite 500

20090105173 - Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by sirna: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a... Agent: Cooper & Dunham, LLP

20090105178 - Rna interference mediated inhibition of platelet-derived endothelial cell growth factor (ecgf1) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating platelet-derived endothelial cell growth factor and/or receptor (ECGF1 and/or ECGF1r) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved... Agent: Sirna Therapeutics, Inc.

20090105182 - Rnai-mediated inhibition of stromal cell-derived factor 1-related targets for treatment of neovascularization-related conditions: RNA interference is provided for inhibition of stromal cell-derived factor 1 (SDF1)-related targets in pathologic neovascularization-related conditions, including those cellular changes resulting from the signal transduction activity of the SDF1 targets that lead directly or indirectly to ocular neovascularization, abnormal angiogenesis, retinal vascular permeability, retinal edema, diabetic retinopathy particularly proliferative... Agent: Alcon

20090105172 - Stabilized aptamers to psma and their use as prostate cancer therapeutics: The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the... Agent: Mintz, Levin, Cohn, Ferris, Glovskyand Popeo, P.C.

20090105185 - Nucleosides with anti-hepatitis b virus activity: A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a β-L-nucleotide, optionally in combination therapy with other drugs for the treatment of HBV or human immuno-deficiency virus (HIV).... Agent: King & Spalding

20090105184 - Positron emission tomography probes for imaging immune activation and selected cancers: Compounds for use as PET probes and methods for synthesizing and using these, comprising [18F]D-FAC and other cytosine and adenosine analogs.... Agent: Venable LLP

20090105186 - Beta-l-n4-hydroxycytosine deoxynucleosides and their use as pharmaceutical agents in the prophylaxis or therapy of viral diseases: The invention relates to β-L-N4-hydroxycytosine nucleo-sides, pharmaceutical agents comprising same, and to the use of said β-L-N4-hydroxycytosine nucleosides and pharmaceutical agents in the prophylaxis or therapy of an infection caused by hepatitis B virus (HBV) or human immunodeficiency virus (HIV). The invention also relates to a method for the preparation... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090105188 - Compositions and methods for treating necrotizing enterocolitis: The present invention relates to a method for treating or preventing necrotizing enterocolitis (NEC) in a human neonate in need thereof, comprising administering to the neonate a pharmaceutically effective amount of a composition comprising a poly(ADP-ribose) synthetase/polymerase (PARP) inhibitor. Also contemplated herein is an infant food or treatment composition comprising... Agent: Calfee Halter & Griswold, LLP

20090105187 - Methods of treating lentivirus infection: The present invention provides methods of identifying agents that reduce a level of active APOBEC3C in a cell. The present invention provides agents that reduce a level of active APOBEC3C in a cell; and compositions comprising the agents. The present invention further provides methods of reducing the mutation rate of... Agent: Bozicevic, Field & Francis LLP

20090105189 - Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same: The present invention is directed to methods and compositions for treating and ameliorating AAMI, hippocampal dysfunction, memory disorders, and brain damage, comprising a composition comprising uridine, an acyl derivative thereof, or a uridine phosphate.... Agent: Pearl Cohen Zedek Latzer, LLP

20090105193 - Crosslinked compounds and methods of making and using thereof: Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one thiol compound with at least one thiol-reactive compound.... Agent: King & Spalding LLP

20090105192 - Glycosaminoglycans derived from k5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation: Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in... Agent: Millen, White, Zelano & Branigan, P.C.

20090105190 - Method for producing fucoidan, fucoidan, and fucoidan-containing composition: A component containing fucoidan having a weight average molecular weight of 1,000,000 to 2,000,000 obtained through the steps of performing hot water extraction of a mozuku alga body of the genus Cladosiphon at pH 6.0 or higher, which ranges from neutral to alkaline, removing low-molecular weight compound through ultrafiltration, and... Agent: Nixon & Vanderhye, PC

20090105191 - Pharmaceutical and dermatocosmetic compositions comprising extract of durio zibenthinus: The present invention relates to dermatocosmetic and pharmaceutical compositions comprising compounds obtained from Durio zibethinus and their use in increasing phase angle and reducing the signs and appearance of photoaging and biological aging.... Agent: Louis C. Paul

20090105195 - Composition comprising microbicidal active ingredients: An antimicrobial composition having a broad-spectrum activity against microorganisms is provided. The antimicrobial composition includes about 0.1 to about 10 percent by weight of a polyurethane polymer of total weight of the antimicrobial composition. The polyurethane polymer is selected from the group consisting of polyolprepolymer and β-Cyclodextrin-polyurethane polymer. The antimicrobial... Agent: Jay M. Schloff Intellipex PLLC

20090105194 - Process for the production of a low molecular weight heparin: The invention provides a process for the production of a very low molecular weight heparin (VLMWH) composition having a VLMWH content, relative to total heparin content, of at least 10% wt, said process comprising chromatographically or chemically or by filtration reducing the relative proportion of heparin having a molecular weight... Agent: Sughrue Mion, PLLC

20090105196 - Use of creatine compounds to treat dermatitis: Creatine compounds for the treatment of dermatitis are described.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090105197 - Use of sodium channel blocking compounds and aspirin in manufacturing drugs for producing analgesia synergistically in mammals: This invention relates to the use of combinations of a sodium channel blocking compound that binds to an SSI or SS2 site of extracellular region of a sodium channel alpha subunit, and aspirin in manufacturing drugs for producing synergistically analgesic effect in mammals. Pharmaceutical compositions based upon this invention can... Agent: Fish & Richardson PC

20090105198 - Novel estrogenic compounds: wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1... Agent: Myers Bigel Sibley & Sajovec

20090105199 - Oligomers of cholesterol, cholesterol sulphate and cholesterol esters and also drugs containing these: The invention relates to new substances which are derived from cholesterol, cholesterol sulphate and cholesterol esters of a natural, semi-synthetic or synthetic origin in that they represent oligomers with a specific type of cross-linkage of the starting substances based on cholesterol.... Agent: Millen, White, Zelano & Branigan, P.C.

20090105200 - Combination therapy: The invention provides a combination therapy for treating cancer and other neoplasms including romidepsin and a proteasome inhibitor. When administered together, romidepsin and a proteasome inhibitor (e.g., bortezomib) interact synergistically to selectively kill malignant cells at low (nanomolar) concentrations. The effect is particularly pronounced in malignant hematological cells (e.g., leukemia,... Agent: Choate, Hall & Stewart LLP

20090105201 - Pulmonary pharmaceutical formulations: The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment... Agent: Elmore Patent Law Group, PC

20090105202 - Androsterone derivatives and method of use thereof: The disclosure provides androsterone derivatives. The derivatives of the disclosure are useful in the treatment of androgen- and estrogen-associated diseases and disorders, including breast cancer.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20090105203 - Compounds for treating viral infections: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20090105205 - Methods of treating disease states using antiangiogenic agents: e

20090105204 - Therapeutic uses for aminosterol compounds: A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the... Agent: Morgan Lewis & Bockius LLP

20090105207 - Copper (1) complex: Copper (I) chloride complex of pyrazinic acid is prepared, characterized by elemental analysis, IR, UV-visible spectra and its crystal structure determined by single crystal diffraction methods. This compound is found to exhibit a very positive influence as a drug, in a pharmaceutical acceptable composition for different incurable diseases, e.g. myopathy... Agent: Mohamed Abd El Rahman Sidahmed Goher C/o Barry G. Magidoff

20090105206 - Copper melphalan and copper tegafur as anti-tumor agents: The present invention relates to the use of copper compounds of general formula Cu(L)2 or hydrates thereof, wherein the ligands L independently denote melphalan and tegafur, as anti-tumor agents.... Agent: Morris Manning Martin LLP

20090105208 - Substituted piperazines as cb1 antagonists: e

20090105209 - Btk protein kinase inhibitors: R2, R3, R4, R5, X1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell... Agent: Grant D. Green Roche Palo Alto LLC

20090105210 - Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted bicyclic pyrimidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is... Agent: Merck And Co., Inc

20090105211 - Inhibitors of hedgehog pathway: e

20090105213 - Lactam compounds useful as protein kinase inhibitors: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20090105212 - Novel adenine compound: wherein A represents an (un)substituted aromatic carbocycle or (un)substituted aromatic heterocycle; L1, L2, and L3 each independently represents linear or branched alkylene, etc.; R1 represents (un)substituted alkyl, (un)substituted aryl, etc.; R2 represents hydrogen or (un) substituted alkyl; R3 represents (un)substituted alkyl, etc., provided that R3 may be bonded to L2... Agent: Birch Stewart Kolasch & Birch

20090105214 - Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes: Compounds of formula (I), wherein R1, R4, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.... Agent: Morgan Lewis & Bockius LLP

20090105217 - 2-phenyl-5-amino-1,3,4-oxadiazoles and their use as nicotinic acetylcholine receptor ligands: Novel oxadiazole derivatives of formula (I) having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of neurological, psychiatric disorders and gastrointestinal disorders through modulation of the nicotinic α7 receptor.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090105216 - 3- (aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors: The present invention encompasses compounds of general formula (1) wherein R1, R2, R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090105215 - Heterocyclic compounds, methods for the preparation thereof, and uses thereof: e

20090105218 - Crth2 receptor ligands for therapeutic use: Compounds of formula (I) are useful in the treatment of disease responsive to modulation of CRTH2 receptor activity, wherein: A represents a carboxyl group —COOH, or a carboxyl bioisostere; L1 is a bond, —CH2—, —OCH2—, —CH2CH2— or —CH═CH—; L2 is CONH—, —NHCO—, SO2NR1—, —NR1SO2 wherein R1 is hydrogen or C1-C3... Agent: Banner & Witcoff, Ltd.

20090105220 - Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives: Novel spirobenzoazepine compounds, novel processes for the preparation of nonpeptide substituted spirobenzoazepine derivatives, and novel processes for the preparation of intermediates in the preparation of such derivatives. Novel intermediates in the preparation of nonpeptide substituted spirobenzoazepine derivatives.... Agent: Philip S. Johnson Johnson & Johnson

20090105219 - Spirolactam tricyclic cgrp receptor antagonists: (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, J, K, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or... Agent: Merck And Co., Inc

20090105221 - Muscarinic receptor antagonists: This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions... Agent: Ranbaxy Inc.

20090105223 - Compound having activity of blocking nmda receptor channel, and pharmaceutical agent using the same: i

20090105222 - Prevention and treatment of functional somatic disorders, including stress-related disorders: Methods for the prevention or treatment of stress-related disorders by administering a therapeutically effective amount of a dual serotonin/norepinephrine reuptake inhibitor to an individual under stress are described. A triple monoamine reuptake inhibitor for serotonin/noradrenaline/dopamine may also be administered to an individual at risk for a stress-related disorder. In a... Agent: Darby & Darby P.C.

20090105225 - 2-substituted 4-benzylphthalazinone derivatives as histamine h1 and h3 antagonists: t

20090105226 - Benzazepine derivatives for the treatment of neurological disorders: The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090105224 - Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor: The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to... Agent: Dykema Gossett PLLC

20090105227 - Thienopyrroles as antiviral agents: The present invention relates to tetracyclic thienopyrrole compounds of formula (I), wherein Ar, A, D1, D2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.... Agent: Merck And Co., Inc

20090105228 - Heterocyclic benzodiazepine cgrp receptor antagonists: (where variables R2, R7, D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these... Agent: Merck And Co., Inc

20090105229 - Purine derivatives as kinase inhibitors: The present invention provides kinase inhibitors of Formula I.... Agent: Eli Lilly & Company

20090105231 - Amide derivatives as rock inhibitors: This invention relates to novel amide derivatives and salts thereof. More particularly, it relates to novel amide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090105230 - Anti-inflammatory medicaments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.... Agent: Hovey Williams LLP

20090105232 - Cyclohexyl or piperidinyl carboxamide antibiotic derivatives: v

20090105233 - Serine-threonine protein kinase and parp modulators: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to... Agent: Morrison & Foerster LLP

20090105234 - Ep4 receptor agonist, compositions and methods thereof: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of... Agent: Merck And Co., Inc

20090105235 - Insecticidal compositions with improved effect: The present invention relates to increasing the activity of crop protection compositions comprising inhibitors of the nicotinic acetylcholine receptor (for example neonicotinoids) through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium or phosphonium salts and penetrants, to the corresponding compositions, to processes for preparing... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090105236 - New pharmaceutically-active compounds for the treatment of respiratory diseases: e

20090105238 - Compounds and relative use for the control of phytopathogens:

20090105237 - Cooling compounds:

20090105239 - 2-pyridine derivatives as inhibitors of neutrophile elastase: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R14, X, W and Z are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Morgan Lewis & Bockius LLP

20090105240 - Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same: The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090105241 - Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives: wherein Ar, Y, R1 and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder (“ADHD”), enhancing... Agent: Cephalon, Inc.

20090105243 - Pyrrolo-triazine aniline compounds useful as kinase inhibitors: e

20090105242 - Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases:

20090105245 - Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor: The present invention provides methods for inhibiting increased vascular permeability and/or pathologic ocular angiogenesis via administration of a combination of one or more molecules that potently inhibit select receptor tyrosine kinases (RTKs) or vascular endothelial growth factor (VEGF) and one or more anti-inflammatory agents.... Agent: Teresa J. SchultzIPLegal (tb4-8)

20090105244 - Thienopyridines as allosteric potentiators of the m4 muscarinic receptor: e

20090105246 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Ropes & Gray LLP

20090105247 - Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors: A compound of formula (I), a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a pharmaceutical composition comprising a compound of... Agent: Matthias Scholl

20090105248 - 3-monosubstituted tropane derivatives as nociceptin receptor ligands: c

20090105249 - 4-phenylsulfonamidopiperidines as calcium channel blockers: The invention relates to piperidinyl compounds of Formula (I): or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1-R3 and Z are defined as set forth in the specification. The invention is also directed to an assay useful for identifying such compounds as N-type calcium channel modulators or blockers.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090105250 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, FGFR3, PDGFRβ and b-Raf kinases.... Agent: Genomics Institute Of The Novartis Research Foundation

20090105252 - Pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease: wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090105251 - Renin inhibitors: e

20090105253 - Triazole derivative and use thereof: wherein R1a, R1b and R2 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted alkoxy, R3 is a group represented by the formula —NHCOR4, —NHSO2R5, —NHCON(R6a)(R6b), —NHCOOR7 or —CONHR8 wherein R4, R5, R6a, R6b, R7 and R8 are each a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090105254 - Vhr protein tyrosine phosphatase inhibitors, compositions and methods of use: Disclosed herein are Vaccinia H1-related (VHR) protein tyrosine phosphatase (PTP) inhibitors that provide a method for treating cancer.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090105255 - Glucokinase activators: s

20090105256 - Prodrugs of ion channel modulating compounds and uses thereof: Prodrugs of ion channeling modulating compounds, including, for example, prodrugs of the ion channel modulating compound of the following formula: are described herein, as well as methods of making and using such prodrugs and pharmaceutical compositions containing such prodrugs.... Agent: Seed Intellectual Property Law Group PLLC

20090105257 - Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090105258 - Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same: This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salt thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090105259 - Acyclic 1,4-diamines and uses thereof: This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain acyclic diamines, which are agonists of TRPV4 channel receptors.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090105260 - Molecules to enhance percutaneous delivery and methods for discovery therefor: An IR spectroscopic technique provides methods for measuring the irritation potential of a formulation and to assess the ability of molecules to enhance the permeability of substances into and through skin using samples comprising stratum corneum. Molecules are screened for their performance as chemical penetration enhancers using a unique in... Agent: Berliner & Associates

20090105261 - Novel substituted pyrazolo[1,5<i>a</i>]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same: The invention relates to novel derivatives capable of increasing the synthesis and/or the release of neurotrophic factors, and therefore able to be used as a human or veterinary medicinal product. The invention also relates to methods for preparing the derivatives and also to the intermediates required for their synthesis.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090105262 - Bridged polycyclic compound based compositions for coating oral surfaces in humans: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups,... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20090105263 - Heterobicyclic compounds as glucokinase activators: p

20090105266 - Organic compounds:

20090105265 - Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin: Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.... Agent: Merck And Co., Inc

20090105264 - Substituted nicotinamide compounds: The present invention relates to a novel class of substituted nicotinamides. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are... Agent: Merck And Co., Inc

20090105267 - Octahydro-pyrrolo[3,4-b]pyrrole n-oxides: The invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides as prodrugs of CNS-active compounds, compositions comprising such compounds, methods for making the compounds, salts, and polymorphs, and methods of treating conditions and disorders using such compounds and compositions. Octahydro-pyrrolo[3,4-b]pyrrole N-oxides of formula (I) are prodrugs of histamine-3 antagonists, and are useful in treating... Agent: Paul D. Yasger Abbott Laboratories

20090105268 - Dihydropyrimidone multimers and their use as human neutrophil, elastase inhibitors: A compound of formula M-L-M (I) wherein L is a linker and each M is independently a group of formula (II) is useful in therapy, e.g. of respiratory diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090105269 - Multifunctional compounds and methods of use thereof: Compositions comprising multifunctional agents and methods of use thereof are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20090105270 - Kinase inhibition and anticancer therapy: This invention relates to novel uses for Compound E in the treatment of diseases, in particular cancer, associated with aberrant kinase expression.... Agent: Merck And Co., Inc

20090105272 - Prodrugs of modulators of abc transporters: The present invention relates to prodrugs of modulators of ABC transporters, particularly, CFTR modulators, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20090105271 - Pyridyl sulfonamides as modulators of ion channels: The present invention relates to pyridyl sulfonamide derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20090105273 - Diacylglycerol acyltransferase inhibitors: e

20090105274 - Indolecarboxylic acid derivative having pgd2 receptor antagonistic activity:

20090105275 - Piperidinyl and piperazinyl modulators of y-secretase: The present invention relates to compounds of Formula I as shown below, wherein the definitions of Het, R0, R1 R2, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's... Agent: Philip S. Johnson Johnson & Johnson

20090105276 - Lindane lotion and methods: The present invention is directed to methods of treatment for scabies using different concentrations of lindane lotions for varying contact times. Compositions of low concentration lindane lotions are also included.... Agent: Winston & Strawn LLP Patent Department

20090105277 - Agent for preventing and/or treating movement disorder: e

20090105279 - Antiviral protease inhibitors:

20090105280 - Novel aromatic nitro compounds:

20090105278 - Selective inhibitors of human corticosteroid syntheses: The invention relates to compounds for selectively inhibiting human corticosteroid syntheses CYP11B1 and CYP11B2, to the production thereof and to their use for treating hypercortisolism and diabetes mellitus or insufficiency of the heart and myocardial fibrosis.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090105281 - Methods of treating inflammation: The invention features compositions and methods for treating inflammation and other immune-related disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090105282 - Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using pde 5 inhibitors: The use of PDE 5 inhibitors in methods for the treatment of benign prostatic hyperplasia or lower urinary tract symptoms and other physiological disorders, as a monotherapy and in combination with other active agents is disclosed. For example, a representative compound useful in the methods of the invention is:... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090105283 - 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors: The present invention discloses 3-hydroquinazolin-4-one derivatives for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cancer, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.... Agent: Cv Therapeutics, Inc.

20090105284 - Aminocyclohexanes as dipeptidyl peptidase-iv for the treatment or prevention of diabetes: The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also... Agent: Merck And Co., Inc

20090105285 - Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor: A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use.... Agent: Novartis Corporate Intellectual Property

20090105286 - Low-molecular inhibitors of cytohesin-family guanine nucleotide exchange factors: The invention relates to drugs and the use thereof, wherein said drugs contain compounds selected from a group comprising general formulas (1), (2), (3) and (4) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. Said drugs are used for treating autoimmune and tumoral diseases and/or for immunosuppresion.... Agent: Davidson, Davidson & Kappel, LLC

20090105287 - Inhibitors of dihydrofolate reductase with antibacterial antiprotozoal, antifungal and anticancer properties: The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090105288 - Carbon linked modulators of gamma-secretase: The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R1, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's disease.... Agent: Philip S. Johnson Johnson & Johnson

20090105289 - 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11 β-hydroxy-Steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090105291 - Phenylalanine enamide derivatives: The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090105290 - Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs: The present invention relates to substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one compounds, to methods for the production thereof, to medicaments containing these compounds and to the use of these compounds for producing medicaments.... Agent: Crowell & Moring LLP Intellectual Property Group

20090105292 - Glucocorticoid receptor modulator compounds and methods: e

20090105294 - Biosynthetic gene cluster for the production of a complex polyketide: A polyketide synthase complex composed of polyketide synthase with 15 total modules, a non-ribosomal peptide synthetase with 1 module, and a cytochrome P450 hydroxylase is described. Also provided are novel Streptomyces species and methods of modified Streptomyces species. Further described are novel compounds, 36-ketomeridamycin, C9-deoxomeridamycin, and C9-deoxoprolylmeridamcyin and uses thereof.... Agent: Wyeth Patent Law Group

20090105293 - Use of thienopyridone derivatives as ampk activators and pharmaceutical compositions containing them: Use of thienopyridone derivatives of formula (I), in which B, R, R6, Y and Z are as defined in the description, and their pharmaceutically acceptable salts, for the preparation of a pharmaceutical composition useful for the treatment of diabetes, metabolic syndrome, related disorders and obesity.... Agent: Millen, White, Zelano & Branigan, P.C.

20090105295 - Hydroxylamine substituted imidazoquinolines: Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with a hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20090105296 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20090105297 - Compounds modulating c-kit activity: Compounds with 7-azaindole core structure with activity toward the receptor protein tyrosine kinase c-kit, compositions useful for treatment c-kit-mediate diseases or conditions, and methods of use thereof, are provided. Further provided are methods of c-kit ligand identification and design.... Agent: Foley & Lardner LLP

20090105298 - Pharmaceutical composition for therapy of interstitial cystitis: A depressant of capsaicin-sensitive sensory nerve, containing quinuclidin-3′-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a salt thereof as an active ingredient, specifically a therapeutic drug of interstitial cystitis, hypersensitive disorder of the lower urinary tract, and/or abacterial prostatitis.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090105299 - C-met modulators and methods of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways... Agent: Leydig Voit & Mayer, Ltd

20090105300 - Amine linked modulators of y-secretase: The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, Y, R1 R2, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including... Agent: Philip S. Johnson Johnson & Johnson

20090105301 - 9a-substituted azalides for the treatment of malaria: The present invention relates to novel 9a-substituted azalides having antimalarial activity. More particularly, the invention relates to 9a-substituted 9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A, 3-O-decladinosyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A and 3-O-decladinosyl-5-O-dedesosaminyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A compounds having antimalarial activity, to the method of preparation, to the method of use, and to pharmaceutically acceptable derivatives thereof having antimalarial activity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090105302 - Macrocylic inhibitors of hepatitis c virus: e

20090105303 - Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20090105304 - Combination therapy for reducing side effects using cannabinoid receptor ligands: The present application describes a method of treating conditions treatable with a CB2 cannabinoid receptor agonist with reduced CB1-mediated side effects using a combination therapy comprising a CB2 agonist and a CB1 ligand, which can be a CB1 antagonist or a CB1 inverse agonist.... Agent: Paul D. Yasger Abbott Laboratories

20090105305 - Therapeutic agents - 550: e

20090105306 - Novel compounds as cannabinoid receptor ligands:

20090105307 - 2-aminooxazolines as taar1 ligands:

20090105308 - Benzoheterocylethylcarboxamide derivatives: The present invention relates to novel benzoheterocyclylethylcarboxamide derivatives of formula (I) in which the substituents are in the description, their process of preparation, their use as fungicides, particularly in the form of fungicidal compositions, methods for the control of phytopathogenic fungi of plants using these compounds or their compositions:... Agent: Ostrolenk Faber Gerb & Soffen

20090105310 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20090105309 - Medicinal compounds: u

20090105311 - Carboxamides:

20090105312 - Solid preparation having improved solubility: When an addition amount of nicotinic acid amide and/or urea is 0.1 to 10% by weight in a solid preparation containing a poorly water soluble drug, and a water-soluble polymer, even a poorly water soluble drug, particularly a drug having a high content can be dissolved out from the preparation... Agent: Birch Stewart Kolasch & Birch

20090105314 - Pharmaceutical agent: wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof, and an agent for the prophylaxis or treatment of sepsis and the like, as well as complications after coronary-artery bypass surgery, which is prepared for administration of ethyl (6R)-6-[(2-chloro-4-fluoroanilino)sulfonyl]-1-cyclohexene-1-carboxylate or a salt thereof... Agent: Foley And Lardner LLP Suite 500

20090105313 - Preventive or therapeutic agent for keratoconjunctival disorder: An object of the present invention is to provide a new medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent prevention and improvement effect in corneal disorder models, and is therefore useful as a preventive or therapeutic agent for a keratoconjunctival disorder such... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090105315 - Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.... Agent: Iplm Group, P.A.

20090105318 - Amidoethylthioether orexin receptor antagonists: The present invention is directed to amidoethylthioether compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck And Co., Inc

20090105316 - Biphenyl thiazole carboxamides: e

20090105317 - Vegf inhibition: The present invention provides methods for inhibiting VEGF production or secretion in a subject comprising administering to the subject an effective amount of a compound of Formula I. The invention also provides methods for the treatment or prevention of conditions associated with abnormal levels of VEGF production or secretion.... Agent: Townsend And Townsend And Crew, LLP

20090105319 - Naphthalene-based inhibitors of anti-apoptotic proteins: wherein each R is independently selected from the group consisting of H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, and NHSO2X, wherein X is selected from the group consisting of an alkyl, a substituted alkyl, an aryl, a substituted aryl, an alkylaryl, and a heterocycle. Compounds of group A may be used for... Agent: Dla Piper LLP (us)

20090105320 - Biodal compositions containing 1,2-benzisothiazolin-3-one and 1,2-dibromo-2,4-dicyanobutane: This invention relates to biocidal compositions in the form of solutions, containing a) 1,2-benzisothiazolin-3-one (formula I) and/or a salt thereof, preferably its alkali metal or ammonium salt, in particular its lithium, sodium or potassium salt; b) 1,2-dibromo-2,4-dicyanobutane (formula (II)); c) at least one solvent which is a mixture of a... Agent: Clariant Corporation Intellectual Property Department

20090105321 - Indole amide derivatives as ep4 receptot ligands: The invention is directed to indoline amide derivatives as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included.... Agent: Merck And Co., Inc

20090105322 - Pharmaceutical composition comprising valsartan: The invention relates to pharmaceutical compositions and a method of preventing or reducing the incidence of AF and thereby reducing the risk of morbidity and mortality in patients having symptomatic heart failure comprising administering to such patient an effective amount of valsartan, or pharmaceutically acceptable salts thereof, alone or in... Agent: Novartis Corporate Intellectual Property

20090105323 - Treatment of edible crops: In the growing of crops for consumption, a method for the removal of pathogens includes the addition to irrigation water for the crops of an anti-pathogen composition and supplying the anti-pathogen composition to the crops prior to harvest while normal irrigation is effected. The anti-pathogen composition is based on halogens,... Agent: Edwin D. Schindler

20090105324 - Imidazole derivatives for use as edg-1 antagonists: The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of... Agent: Astrazeneca R&d Boston

20090105325 - Substituted pyrazolecarboxylic acid anilide derivative or salt thereof, intermediate thereof, agent for agricultural and horticultural use, and use thereof: wherein R1 is H, alkyl, alkylcarbonyl, alkenylcarbonyl, cycloalkyl, phenylalkyl, phenylcarbonyl and the like; R2 is H, halogen, alkyl, CN, OH, alkoxy, phenoxy, phenylthio, phenylsulfonyl and the like; G is alkyl, alkenyl, alkynyl, cycloalkyl, C3-C10 cycloalkenyl and the like; Z is O or S; X is H, halogen, CN, NO2, alkyl... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090105326 - Crystalline chemotherapeutic: N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼ Ethanolate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it is disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090105327 - Dibenzocycloheptane compounds and pharmaceuticals containing these compounds: in which R1, R2, R3, R4, X and Y have the meanings indicated in the description. These compounds have immunomodulating effects, as well as an inhibiting or regulating effect on the release of IL-1β and/or TNF-α. They can therefore be used for the treatment of diseases associated with a disturbance... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090105328 - Amino acid compounds: An Amino Acid Compound is described. The Amino Acid Compound may comprise an Amino Acid and one of a Nitrate and a Nitrite. The Amino Acid may be one of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine.... Agent: Booth Udall, PLC

20090105329 - Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof an amount of a histone deacetylase (HDAC) inhibitor, e.g., suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and an amount of one... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20090105330 - Admixture of carotenoids and isoflavonoids for treating cutaneous symptoms of aging: Intimate admixtures of at least one carotenoid and at least one isoflavonoid are well suited for treating the undesirable cutaneous signs of skin aging, in particular the determination of the skin and/or of the mucous membranes by inhibiting the activity and/or the expression of collagenases and by increasing the synthesis... Agent: Buchanan, Ingersoll & Rooney PC

20090105331 - Compositions of active ingredients: The present invention relates to compositions containing fat-soluble active ingredients and/or colorants in a matrix based on improved modified polysaccharides, i.e. modified polysaccharides where parts were separated, and to a process for preparing these compositions as well as to these improved modified polysaccharides themselves and a process for the manufacture... Agent: Nixon & Vanderhye, PC

20090105332 - Processes of making sesquiterpenoid tashironin, its analogs and their uses: e

20090105333 - Melatonin agonist treatment: This invention provides methods of administering (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclo-propyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder.... Agent: Hoffman Warnick LLC

20090105334 - Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain: wherein phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl... Agent: Philip S. Johnson Johnson & Johnson

20090105335 - Polyunsaturated fatty acid monovalent and divalent metal salt synthesis: Disclosed herein are methods for the preparation of a free-flowing, storage-stable fatty acid metal salt product by forming a reactive admixture comprising (a) an unsaturated fatty acid glyceride feedstock; and (b) from about 1 mol to about 3 mol of at least one monovalent metal hydroxide or at least one... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090105336 - Beneficial effects of increasing local blood flow: The present invention provides a treatment for enhancing the ability of the body to heal wounds. A topical cream is described which improves blood flow by the transdermal delivery of the nitric oxide precursor L-Arginine either alone or with an adjunct, theophylline. The delivery of the active agents is accomplished... Agent: Wolf Greenfield & Sacks, P.C.

20090105337 - Esters of florfenicol: e

20090105338 - Deuterium-enriched gabexate mesylate: The present application describes deuterium-enriched gabexate mesylate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090105339 - Curative drug for neurodegenerative diseases: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6 or alkoxycarbonyl group with a carbon number of 2 to 6. A curative drug for neurodegenerative diseases can be prepared... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090105340 - Composition and/or method for preventing recurrence of stroke: By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the... Agent: Birch Stewart Kolasch & Birch

20090105341 - Process for the production of trans-10, cis 12 octadecadienoic acid: The present application is directed to a process for the production of trans-10, cis-12 conjugated linoleic acid in a transgenic microorganism comprising the steps of: (a) introducing into said microorganism at least one nucleic acid molecule encoding a trans-10, cis-12 conjugated linoleic acid isomerase, (b) culturing the transgenic microorganism obtained... Agent: Connolly Bove Lodge & Hutz, LLP

20090105342 - Pufa supplements: Edible formulations, such as polyunsaturated fatty acids (PUFAs) such as pharmaceutical compositions or nutritional supplements, are disclosed comprising arachidonic acid (ARA). They are adapted to deliver from 150 mg to 1 g per day of ARA and may contain other PUFAs, for example docosahexaenoic acid (DHA). The DHA dosage is... Agent: Nixon & Vanderhye, PC

20090105343 - Cancer therapy and medicaments therefor: The present invention relates to a novel cancer therapy, particularly, but not exclusively, to a prostate, bladder and breast cancer therapy and to Compositions and medicaments for use in said therapy. In one aspect there is provided a method of treating a patient afflicted with cancer comprising administering to the... Agent: Paul D Greeley Ohlandt, Greeley, Ruggiero & Perle, LLC

20090105345 - Amide linked modulators of gamma-secretase: The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, R1 R2, R3, R4, R5, R6, R7, and R8 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's disease.... Agent: Philip S. Johnson Johnson & Johnson

20090105344 - Biphenyl carboxylic acids and derivatives thereof: e

20090105346 - Novel crystalline forms of armodafinil and preparation thereof: The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms of armodafinil, pharmaceutical formulation thereof, and method of treating excessive sleepiness using the formulations of the invention.... Agent: Kenyon & Kenyon LLP

20090105347 - Thyronamine derivatives and analogs and methods of use thereof: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed... Agent: Woodcock Washburn LLP

20090105348 - Treatment of migraine headaches using antiestrogens: A method of preventing the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches, especially accompanied by prodrome and/or aura, comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently far in advance of the... Agent: Norris, Mclaughlin & Marcus, Pa

20090105349 - Androgen modulators: The present invention is directed to the discovery of a new class of androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease sebum secretion and to stimulate hair growth.... Agent: Pfizer Inc.

20090105350 - Process for the preparation of atovaquone: The present invention provides a process for the preparation of atovaquone exhibiting characteristic peaks (expressed in degrees 2θ±0.2°θ) at approximately one or more of the positions: about 7.0, 9.7, 14.2, 14.8, 17.0, 19.2, 20.4, 22.1, 22.7, 26.9 and 28.7, which comprises: (a) providing a solution comprising atovaquone in an aprotic... Agent: M. Carmen & Associates, PLLC

20090105351 - Micellar drug delivery systems for hydrophobic drugs: This invention provides compositions comprising a hydrophobic drug, a biocompatible micelle forming polymer, and a biocompatible low molecular weight, water-soluble polymer. Also provided are devices for injection of such compositions and for the use of such compositions to form hydrophobic drug containing micelles within the body of a patient.... Agent: Seed Intellectual Property Law Group PLLC

20090105353 - Cosmetic oil-in-water emulsion: in which R1 and R3 denote, independently of one another, an alkyl radical containing from 1 to 25 carbon atoms; R2 denotes a spacer consisting of a linear or branched alkylene chain containing from 1 to 12 carbon atoms; X and Y denote, independently of one another, a group —(C2H4O)a—(C3H6O)bZ;... Agent: Oliff & Berridge, PLC

20090105352 - Functionalized biodegradable triclosan monomers and oligomers for controlled release: This invention relates to the discovery of functionalized triclosan monomers and oligomers that, when incorporated into a substrate of, or applied as part of a coating to, medical devices and/or consumer products may extend the duration of antimicrobial properties to the medical devices and/or consumer products.... Agent: Feldmangale, P.A.

  
04/16/2009 > patent applications in patent subcategories. category listing, related patent applications

20090099060 - Modulation of line-1 reverse transcriptase: A reverse transcriptase encoded by L-1 (LINE-1) has been identified as a target molecule for treating or preventing cancers induced or mediated by this molecule. Method of treating or preventing such cancers in patients involves administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of... Agent: Stanley P. Fisher Reed Smith

20090099062 - Pyrvinium for the treatment of cancer: The present invention concerns a pyrvinium compound or an analog thereof for the treatment of cancers. This compound inhibits Wnt activity in the cells of cancers such as adrenocortical, hepatocellular, hepatoblastoma, malignant melanoma, ovarian, Wilm's tumor, Barrett's esophageal, glioma, bladder, breast, gastric, head & neck, lung cell, mesothelioma, and cervical... Agent: Fulbright & Jaworski L.L.P.

20090099063 - Ssx-2 peptides presented by hla class ii molecules: The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions... Agent: Wolf Greenfield & Sacks, P.C.

20090099061 - Synthesis of carotenoid analogs or derivatives with improved antioxidant characteristics: A method is described for synthesizing and administering carotenoid compounds with improved antioxidant characteristics. In some embodiments, extension or improvement of conjugation may be employed in structural modification of carotenoids. In other embodiments, reduction of ring/chain steric hindrance may improve the lambda max, and hence, the overall antioxidant capability, of... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20090099065 - Acylated single chain insulin: The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue being substituted for the natural amino acid residue in one of the positions A12-A23 in the human insulin A-chain... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090099064 - Derivatized insulin oligomers: The present invention provides oligomers of phosphorylated insulin and formulations thereof. The oligomeric derivatives of the invention exhibit pharmacodynamic properties that are significantly improved over native insulin or other intermediate-acting or basal insulins, for example NPH, Lantus or Detemir, in that they demonstrate a 4-fold higher therapeutic index and a... Agent: Gowling Lafleur Henderson LLP

20090099066 - Tissue specific peptide conjugates and methods: Cell-penetrating peptides useful for targeting a therapeutic compound to a selected mammalian tissue, methods for their identification, methods of forming conjugate compounds containing such peptides, and conjugates formed thereby are disclosed. The cell-penetrating peptides are 8 to 30 amino acid residues in length and consist of subsequences selected from the... Agent: King & Spalding LLP

20090099067 - Glycosylated g-csf: The invention relates to G-CSF molecules having certain O-linked oligosaccharide structures.... Agent: Synageva Biopharma Corp.

20090099068 - On-growth inhibiting compounds: An on-growth inhibiting agent, for the inhibition and/or prevention of on-growth of biological organisms on objects or living beings, includes at least one cyclotide, and a suitable carrier medium. A plant extract containing a mixture of cyclotides is also usable.... Agent: Young & Thompson

20090099086 - Activin-actriia antagonists and uses for promoting bone growth: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.... Agent: Ropes & Gray LLP

20090099073 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090099085 - Amylin derivatives: The present invention relates to novel amylin derivatives having a protracted action profile, to pharmaceutical compositions comprising these derivatives and to the use of the derivatives for the treatment of diseases related to obesity, diabetes and other metabolic disorders.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090099075 - Chimeric keratin-binding effector proteins: The invention relates to chimeric keratin-binding effector proteins and their use in dermocosmetics.... Agent: Connolly Bove Lodge & Hutz, LLP

20090099083 - Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis: Provided are compositions and methods for stimulating an immune response against Mycobacterium avium subspecies paratuberculosis (MAP). The compositions include a recombinant polypeptide that contains from its N-terminus to C-terminus a C-terminal fragment of MAP protein Map3527, a Map1519 protein amino acid sequence, followed by an N-terminal portion of Map3527. The... Agent: Marjama Muldoon Blasiak & Sullivan LLP

20090099087 - Human kunitz-type inhibitor with enhanced antifibrinolytic activity: A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2). In another aspect, methods of treating a subject afflicted with cancer or a precancerous condition are described.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090099089 - Methods and compositions for healing and repair of articular cartilage: Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in... Agent: Wyeth/finnegan Henderson, LLP

20090099070 - Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder: The invention provides a method for preventing or treating male erectile dysfunction or female sexual arousal disorder by administering an effective amount of one or more factors from a group of factors including vascular endothelial growth factor, brain-derived neurotrophic factor, basic fibroblast growth factor, neurotrophin-3, neurotrophin-4, or angiopoietin-1, wherein the... Agent: Morrison & Foerster LLP

20090099080 - Mitochondria-targeted anti-tumor agents: Described are mitochondria-targeted anti-tumor agents, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation.... Agent: Fish & Richardson PC

20090099074 - Modulating food intake: The present disclosure relates to a conjugate comprising a PYY peptide or a functional derivative thereof which is coupled to a reactive group. Such a reactive group reacts with albumin so as to form a stable covalent bond therewith. The disclosure further provides methods of reducing water or food intake... Agent: Lowrie, Lando & Anastasi, LLP

20090099069 - Modulators of alpha-synuclein toxicity: Disclosed are compositions and methods for modulating expression of genes that function at the step of ER of Golgi trafficking. Compounds that modulate expression of these genes of activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to threat of prevent synucleinopathies such as... Agent: Fish & Richardson P.C.

20090099072 - Motif of the beclin protein which interacts with anti-apoptotic members of the bcl-2 protein family, and uses: The invention relates to a method of identifying modulators of programmed cell death, comprising an interaction between a motif of Beclin protein and an anti-apoptotic member of the family of Bcl-2 proteins and the detection of said interaction be means of fluorescence polarisation. The modulators identified on the basis of... Agent: The Firm Of Hueschen And Sage

20090099078 - Nogo receptor antagonists: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof,... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090099079 - Novel fungal enzymes: This invention relates to novel enzymes and novel methods for producing the same. More specifically this invention relates to a variety of fungal enzymes. Nucleic acid molecules encoding such enzymes, compositions, recombinant and genetically modified host cells, and methods of use are described. The invention also relates to a method... Agent: Sheridan Ross PC

20090099076 - Obg3 globular head and uses thereof: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090099082 - Production of polyurethane foams: The invention relates to a process for producing polyurethane foams, by frothing and drying mixtures of specific polyurethane dispersions and crosslinkers.... Agent: Connolly Bove Lodge & Hutz, LLP

20090099071 - Sugar chain-containing albumin, production method thereof and use thereof: Glycosylated albumin as a drug carrier for a DDS targeting the liver (particularly kupffer's cell) can be provided by mutating a DNA encoding albumin to encode a mutant albumin containing a partial amino acid sequence permitting glycosylation modification by eukaryotic cell, preferably a consensus sequence of N-linked sugar chain, introducing... Agent: Leydig Voit & Mayer, Ltd

20090099081 - Synthetic axmi-004 delta-endotoxin genes and methods for their use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided, particularly synthetically-derived coding sequences. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants... Agent: Alston & Bird LLP

20090099088 - System for inhibiting pathogenicity in the rice-blast fungus magnaporthe grisea: In Magnaporthe species and other plant pathogenic fungal species, the appressoriu, (infection structure) is responsible for breaching the host plant cell wall and gaining entry into the host tissues. Magnaporthe ABC3 protein is an MDR transporter that plays an important role during host penetration and also is involved in regulating... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090099084 - Treatment: The invention provides use of a TSG-6 polypeptide, or a polynucleotide encoding an TSG-6 polypeptide, in the manufacture of a medicament for the treatment or prevention of a bone disease or condition associated with bone resorption by osteoclasts.... Agent: Clark & Elbing LLP

20090099077 - Treatment of rett syndrome and other disorders: The invention relates to methods for treatment of Rett Syndrome and other disorders of synaptic function and maturation using IGF1, (1-3)IGF-1, (1-3)IGF-1 analog(s) and/or related therapeutic molecules.... Agent: Wolf Greenfield & Sacks, P.C.

20090099090 - Hla-a24-restricted cancer antigen peptides: HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090099092 - Methods for stimulating fibroblast proliferation using substance p analogs: Provided herein are methods and compositions for stimulating or promoting fibroblast proliferation. In one embodiment, provided herein are methods and compositions for promoting or enhancing wound healing.... Agent: Jones Day

20090099091 - Oligopeptide tyrosinase inhibitors and uses thereof: Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Peptide sequences disclosed include KFEKKFEK and YRSRKYSSWY.... Agent: Peters Verny , L.L.P.

20090099093 - Peptide tyrosinase inhibitors and uses thereof: Disclosed are peptides, which inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. The peptides are characterized by sequences RADRADC and PLG-OH. Methods of skin treatment are... Agent: Peters Verny , L.L.P.

20090099094 - Use of somatostatin agonists to treat medullary thyroid carcinoma: The present invention is directed to a method of determining a treatment to effectively combat medullary thyroid carcinoma and to suppress the secretion of calcitonin from medullary thyroid carcinoma cells. The present invention also provides a method of suppressing the secretion of calcitonin from medullary thyroid carcinoma cells and decreasing... Agent: Alan F. Feeney Biomeasure, Incorporated

20090099095 - Novel neuroprotective peptide: The field of the present invention is a novel neuroprotective peptide, pentinin, having neuroprotective properties. More particularly, the field of the present invention relates to the ability of pentinin (SEQ ID NO: 1) to affect endogenous undifferentiated stem cells to positively modulate neural damage and the use of such peptide... Agent: Lynn E Barber

20090099096 - Aza-peptide protease inhibitors: e

20090099097 - Enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the... Agent: Ropes & Gray LLP

20090099098 - Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application: The invention is related to the medicinal means of correction of metabolic vascular syndrome and diseases, associated with disordered vascular wall permeability and capillaries fragility, and can be used as a means of enhancing capillaries resistance. There is proposed a peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1... Agent: Leydig Voit & Mayer, Ltd

20090099100 - Compositions and methods for treating amyloidosis: or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R1 and R2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C═O), thiocarbonyl (C═S), sulfonyl (SO2), or sulfoxide (S═O) group. “k”... Agent: Lahive/ Neurochem

20090099101 - Drugs, foods or drinks with the use of algae-derived physiologically active substances: foods, drinks, cosmetics, etc. containing as the active ingredient at least one member selected from the group consisting of the above-mentioned compound, its aldehyde, its hydrate and 2-O-methylated derivatives thereof and soluble sugar compounds containing the above compound. This compound also shows, for example, an apoptosis-inducing activity, a carcinostatic activity... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090099099 - Isoflavone glycosides as peroxisome proliferator-activated receptor-alpha modulator: A method of treating or preventing diseases related to modulation of PPAR-α in comprising administering to a human or other mammals in need of such treatment an effective amount of plant material derived from plants of the genera Puerila Lobata.... Agent: Hong Wang

20090099102 - Ginkgolides in the treatment and prevention of ovarian cancer: The present invention is directed to pharmaceutical compositions and nutritional supplements that contain large amount of ginkgolides, particularly ginkgolide A or B, and for which, the other components normally found in Ginkgo biloba extracts have been removed. The compositions may be administered to women to prevent or treat ovarian cancer,... Agent: Law Office Of Michael A. Sanzo, LLC

20090099103 - Combinations of therapeutic agents for treating cancer: The invention relates to a combination comprising an Erb-B and VEGF receptor inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.... Agent: Novartis Corporate Intellectual Property

20090099104 - Substituted indazoles-o- glucosides: Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090099105 - Content dependent inhibitors of cytidine deaminases and uses thereof: This invention relates to cytidine deaminase inhibitors (Cytidine deaminase inhibitors) of cytidine deaminases and uses thereof.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090099106 - Quinoline derivatives for modulating dna methylation: Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation... Agent: Seed Intellectual Property Law Group PLLC

20090099123 - Antisense microrna and uses therefor: Provided herein are methods to suppress specificity protein (Sp) activity in a cell associated with a cell proliferative disease. The methods are effective to inhibit a microRNA in the cell using an antisense microRNA oligonucleotide which results in an increase in expression of a specificity protein (Sp) suppressor gene thereby... Agent: Benjamin Aaron Adler Adler & Associates

20090099110 - Antiviral oligonucleotides: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for... Agent: Ogilvy Renault LLP

20090099109 - Interfering rnas against the promoter region of p53: The present invention relates to the inhibition of p53 transcription by interfering with the activity of a p53 promoter using inhibitory double-stranded RNAs. Use of these inhibitory RNAs in the treatment of cancers also is disclosed.... Agent: Fulbright & Jaworski L.L.P.

20090099107 - Methods and compositions for inhibition of nuclear factor kappab: A series of p105-based NF-κB super repressors, designated p-105(sr), have been designed. The p105(sr), no longer generates p50 and undergoes signal-induced degradation, effectively inhibiting all NF-κB activities. Additionally, p105(sr) significantly enhances tumor necrosis factor alpha (TNF-α)-mediated killing of MT1/2 skin papilloma cells when p50 homodimer activity is elevated. p105(sr) is... Agent: Edwards Angell Palmer & Dodge LLP

20090099111 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of... Agent: King & Spalding

20090099112 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of... Agent: King & Spalding

20090099113 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of... Agent: King & Spalding

20090099114 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of... Agent: King & Spalding

20090099108 - Oligonucleotide decoys and methods of use: The present invention describes reagents and methods for using a concatemerized double-stranded oligonucleotide molecules (CODN) for transcription factor decoys. In one embodiment, the concatemers consist of a variable number of end-to-end repeated copies of a short (more than 5, 10, 15, 20, 2, 3035, 40, 45, 50, 75, 100, or... Agent: Dinsmore & Shohl, LLP

20090099125 - Pan cancer oncolytic vectors and methods of use thereof: Replication-competent adenoviral vectors which selectively replicate in cancer cells are provided. The replication-competent viral vectors comprise an E2F responsive promoter and/or a telomerase promoter operatively linked to an adenoviral coding region. The replication-competent adenoviral vectors effectively replicate in a variety of types of cancer cells and find broad utility in... Agent: Ropes & Gray LLP

20090099116 - Rna interference mediated inhibition of fos gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating c-Fos gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of c-Fos gene expression and/or activity by... Agent: Sirna Therapeutics, Inc.

20090099121 - Rna interference mediated inhibition of matrix metalloproteinase 13 (mmp13) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating matrix metalloproteinase (e.g., MMP13) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of gene expression and/or... Agent: Sirna Therapeutics, Inc.

20090099120 - Rna interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and... Agent: Sirna Therapeutics, Inc.

20090099115 - Rna interference mediated inhibition of myc and/or myb gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating Myc and/or Myb gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Myc and/or Myb gene... Agent: Sirna Therapeutics, Inc.

20090099117 - Rna interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating myostatin (GDF8) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of myostatin gene expression and/or activity... Agent: Sirna Therapeutics, Inc.

20090099119 - Rna interference mediated inhibition of ras gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating RAS, e.g. K-RAS, H-RAS, and/or N-RAS gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of RAS,... Agent: Sirna Therapeutics, Inc.

20090099118 - Rna interference mediated inhibition of stearoyl-coa desaturase (scd) gene expression using short interfering nucelic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating Stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Stearoyl-CoA desaturase (SCD) gene... Agent: Sirna Therapeutics, Inc.

20090099124 - Short interfering rna as an antiviral agent for hepatitis c: Hepatitis C virus (HCV) is a major cause of chronic liver disease and affects over 270 million individuals worldwide. The HCV genome is a single-stranded RNA that functions as both a messenger RNA and replication template, making it an attractive target for the study of RNA interference. Double-stranded short interfering... Agent: Amgen Inc. Law Department

20090099122 - Use of cpg oligodeoxynucleotides to induce epithelial cell growth: This disclosure provides a method of inducing epithelial cell growth. The method includes administering an effective amount of a K-type CpG oligonucleotide, thereby inducing epithelial cell growth. The epithelial cell can be in vivo or in vitro. Methods are also provided for inducing wound healing in a subject. The methods... Agent: Klarquist Sparkman, LLP

20090099126 - Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection: The present invention provides ribonucleoside 2′,3′-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as... Agent: Merck And Co., Inc

20090099127 - Nematicidal compositions and methods: A nematicidal composition includes (a) at least one carbamate and (b) at least one neonicotinoid and/or chloronicotinyle. In one exemplary embodiment, the carbamate can be an oxime carbamate, such as thiodicarb and the neonicotinoid can be a nitroguanidine. In one specific embodiment, the nitroguanidine includes imidacloprid and/or clothianidin. An exemplary... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090099128 - Composition and method for treating autoimmune disease and mucosal disorder: The present invention provides the composition and the method for treating autoimmune diseases and a mucosal disorder via oral-tolerance induction and innate immunity promotion. The composition for treating the autoimmune disease and mucosal disorder includes the polysaccharide prepared from a plant, wherein the plant belongs to Genus Dendrobium.... Agent: Volpe And Koenig, P.C.

20090099129 - Inulin of very high chain length: The invention relates to a long-chain inulin and its preparation from artichoke roots, to its use in foodstuffs and cosmetic preparations and to foodstuffs and cosmetic preparations which comprise the long-chain inulin.... Agent: Hunton & Williams LLP Intellectual Property Department

20090099130 - Methods and compositions for preventing and treating a disease related to glycan dysregulation: Contemplated compositions and methods are directed to prevent and/or treat various autoimmune diseases that are typically associated with glycan dysregulation, and especially autoimmune demyelinating diseases. Further especially contemplated aspects include animal models and systems for screening compounds to treat and/or prevent such diseases.... Agent: Howson & Howson LLP

20090099131 - Inhibitors of fatty acid amide hydrolase: The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for... Agent: Choate, Hall & Stewart LLP

20090099132 - Proteasome inhibitors: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20090099133 - Isoquinolines derivatives as igf-1r inhibitors: Compounds of the formula (I) were synthesized. They were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.... Agent: Harness, Dickey & Pierce, P.L.C

20090099134 - Treatment of dna damage related disorders: The present invention provides methods and compositions for prophylaxis and treatment of a variety of disorders including DNA damage related disorders, cancer, ischemia, oxidative stress, atherosclerosis, and stroke using a chloroquine compound.... Agent: St. Jude Children''s Research Hospital C/o Darby & Darby P.C.

20090099136 - Dioxolane thymine phosphoramidates as anti-hiv agents: Disclosed are dioxolane thymine phosphoramidate compounds, compositions, and methods for using dioxolane thymine phosphoramidate compounds and compositions to treat viral infections, such as HIV infections.... Agent: Merchant & Gould PC

20090099135 - Pest control compositions and methods: Embodiments of the present invention provide compositions for controlling a target pest including a pest control product and at least one active agent, wherein: the active agent can be capable of interacting with a receptor in the target pest; the pest control product can have a first activity against the... Agent: Sonnenschein Nath & Rosenthal LLP

20090099137 - Anti-inflammatory compounds and uses thereof: b

20090099138 - Pharmaceutical combination: A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form comprising said combination, salt, or compound; as well as a method of treating... Agent: Crowell & Moring LLP Intellectual Property Group

20090099139 - Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use: The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived... Agent: Wilmerhale/nitromed

20090099140 - 20-alkyl, gemini vitamin d3 compounds and methods of use thereof: The invention provides 20-alkyl Gemini vitamin D3 compounds, methods for using the compounds to treat vitamin D3 associated states and pharmaceutical compositions containing the compounds.... Agent: Edwards Angell Palmer & Dodge LLP

20090099141 - Compositions and methods for treating vitamin d deficiencies: The present invention provides for: (a) an oral dosage of vitamin D3 for humans sufficient to maintain a serum level above a minimally sufficient level and below a toxic level when administered according to a schedule of at least one dosage a week up to at least one dosage a... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20090099146 - Compositions containing sterol-derived esters: The invention relates to sterol fatty acid esters of average chained fatty acids, having a chain length of 8 and 10 carbon atoms in a fatty acid distribution C8 to C10 (weight ratio) from 95:5 to 5:95, preferably, fatty acid distributions of C8 to C10 (weight ratio) from 90:10 to... Agent: Fox Rothschild LLP

20090099144 - Oral contraception (long-cycle regimen and 21-days-regimen with 30 mg ethinylestradiol and 2 mg dienogest) without treatment of thrombosis/hemostasis: The kit for long-cycle administration of a monophasic oral contraceptive preparation without affecting blood pressure advantageously consists of 84 daily dose units, which each contains a combination of 2.0 mg of dienogest and 0.030 mg of ethinyl estradiol, and 7 daily dose units that do not contain any active contraceptive... Agent: Striker, Striker & Stenby

20090099142 - Pharmaceutical compositions comprising esterified estrogens and methyltestosterone and method of using same: The present invention relates generally to pharmaceutical compositions comprising esterified estrogens, methyltestosterone and one or more pharmaceutical excipients. Methods for preparing and using such compositions are also provided.... Agent: Mayer Brown LLP

20090099145 - Process for producing a single-phase pharmaceutical preparation for limiting/reducing the risk of deep venous thrombosis in association with oral contraception: e

20090099143 - Tetrahydro-indazole cannabinoid modulators:

20090099148 - Combinations comprising antimuscarinic agents and pde4 inhibitors: Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma... Agent: Hoxie & Associates LLC

20090099147 - Non-steroidal progesterone receptor modulators: m

20090099149 - Bioadhesive film: Bioadhesive films for delivery of active agent to the mucosa are disclosed. Particularly, bioadhesive films for treating the vaginal mucosa are disclosed.... Agent: Pepper Hamilton LLP/wyeth

20090099150 - Methotrexate combinations for treating inflammatory diseases: Compounds, methods and kits for treating inflammatory diseases are disclosed. The treatment comprises administering to a patient in need thereof, methotrexate and a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.... Agent: Sonnenschein Nath & Rosenthal LLP

20090099151 - Modified release pharmaceutical compositions and processes thereof: Novel modified release pharmaceutical composition comprising at least one active agent(s); a polymer system in an amount less than about 80% w/w of the composition comprising at least two swellable pH independent polymers wherein at least one is hydrophilic; optionally other pharmaceutically acceptable excipients is provided. Process for preparation of... Agent: Ladas & Parry LLP

20090099152 - 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same: The present invention relates to 2-alkoxy-3,4,5-trihydroxyalkylamide benzodiazepine compounds, to pharmaceutical compositions comprising such compounds, to methods of treatment comprising administering such compounds, to processes for the preparation of such compounds, and to intermediate precursors to such compounds.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090099153 - Novel 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use: This invention relates to novel 8,10-diaza-bicyclo[4.3.1]decane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the... Agent: Birch Stewart Kolasch & Birch

20090099154 - Pharmaceutical sustained release compositions and processes thereof: Pharmaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, solvates, or salts thereof; preferably an antiviral active agent is provided. Also provided is a process of preparation of such composition and method of using them. The sustained release compositions of the present... Agent: Ladas & Parry LLP

20090099155 - 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists: a

20090099156 - Heterocyclic compounds as ccr2b antagonists: Compounds of formula (I) Q-L-W—C(═X)-Z-P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently... Agent: Morgan Lewis & Bockius LLP

20090099157 - Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s: Tetrahydro-pyrazolo-pyridine thioether compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.... Agent: Woodcock Washburn LLP

20090099158 - Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor: Certain substituted tetrahydroisoquinoline compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20090099159 - Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds: r

20090099160 - 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors:

20090099161 - Substituted imidazoquinolines and imidazonaphthyridines: Imidazoquinolines and imidazonaphthyridines with a substituent containing a functional group, e.g., an amide, sulfonamide, urea, or heterocyclyl group, at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and... Agent: Wolf Greenfield & Sacks, P.C.

20090099163 - Glucokinase activators: i

20090099164 - Phenylaminopropanol derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly... Agent: Woodcock Washburn LLP/wyeth

20090099162 - Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias:

20090099165 - Protein kinase inhibitors:

20090099166 - C10-substituted camptothecin analogs: The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug... Agent: Scott A. Whitaker, Ph.d., J.d. Senior Intellecual Property Counsel

20090099168 - Hiv integrase inhibitors: wherein G, Q, bond a, R5, R6 and R7 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se... Agent: Merck And Co., Inc

20090099167 - Organic compounds: The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.... Agent: Foley And Lardner LLP Suite 500

20090099169 - Benzofuran compounds as ep1 receptor antagonists: e

20090099172 - 6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile derivatives: to pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S related diseases such as atherosclerosis, obesity, inflammation and immune disorders, such as rheumatoid arthritis, psoriasis, cancer, and chronic pain, such as neuropathic pain.... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090099174 - Combination 059: This invention relates to a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to;... Agent: Astrazeneca R&d Boston

20090099171 - Diazaquinolones that inhibit prolyl hydroxylase activity: i

20090099173 - Pyridopyridazine compounds, compositions and methods of use: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.... Agent: Amgen Inc.

20090099170 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Ropes & Gray LLP

20090099178 - Indazole compounds and methods of use thereof: This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis... Agent: Jones Day

20090099175 - Phosphodiesterase 10 inhibitors: The present invention if directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and... Agent: Jones Day

20090099177 - Pyridyl compounds: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein R1, and R2, and R3 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090099176 - Pyrrolopyridine-2-carboxylic acid amides: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.... Agent: Osi Pharmaceuticals, Inc.

20090099179 - Compounds for diseases and disorders: The invention provides novel compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH2, -L-C(═O)NH(C1-3 alkyl), -L-C(═O)N(C1-3 alkyl)2, -L-S(═O)2(C1-3alkyl), -L-S(═O)2NH2, -L-S(═O)2N(C1-3 alkyl)2, -L-S(═O)2NH(C1-3 alkyl), -L-C(═O)NHOH, -L-C(═O)CH2NH2, -L-C(═O)CH2OH, -L-C(═O)CH2SH, -L-C(═O)NHCN, -L-NHC(═O)ORo, -L-C(═O)NHRo, -L-NH(C═O)NHRo, -L-C(═O)N(Ro)2,... Agent: Myriad Genetics Inc. Intellecutal Property Department

20090099180 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia,... Agent: Eli Lilly & Company

20090099182 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated... Agent: Eli Lilly & Company

20090099181 - Sulfoximines as kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Agent: Robert J. Baran (t2-7h) Allergan, Inc.

20090099183 - Pyrimidines and uses thereof: The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor-cells.... Agent: Seed Intellectual Property Law Group PLLC

20090099185 - P38 map kinase inhibitors: wherein: G is —N═ or —CH═; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5-13 ring members; R6 is hydrogen or optionally substituted C1-C3 alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a... Agent: Banner & Witcoff, Ltd.

20090099184 - Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors: Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.... Agent: Micheal P. Morris Boehringer Ingelheim Usa Corporation

20090099186 - Inhibitors of viral replication: The embodiments provide compounds of the general Formulas I-IV, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in... Agent: Knobbe Martens Olson & Bear LLP

20090099187 - Novel 8-sulfonyl-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor: The present invention relates to new compounds of formula (I), wherein R1 to R12, P, X, Q and n are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090099188 - Microbicidal composition based on formaldehyde donor compounds and antioxidants: A microbicidal composition and its method of use for preserving technical products such as fuels and lubricants. The composition is made up of at least one formaldehyde donor compound and at least one antioxidant. The antioxidant is either a gallic ester, a phenol derivative, a L-ascorbic acid, including salts and... Agent: Young & Thompson

20090099189 - Crth2 receptor ligands for medicinal uses: Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, wherein A represents a carboxyl group —COON, or a carboxyl bioisostere; A1, is hydrogen or methyl; ring Ar1 is an optionally substituted... Agent: Banner & Witcoff, Ltd.

20090099190 - Kinase inhibitors useful for the treatment of proliferative diseases: The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase... Agent: Hovey Williams LLP

20090099191 - Inhibition of nf-kb: The present invention is generally related to the modulation of cell growth or apoptosis. Compositions for modulating cell growth or apoptosis, methods of use thereof, and methods of identification thereof are described.... Agent: Polsinelli Shugart PC

20090099192 - Substituted 1h-pyrrole-2,5-diones: e

20090099193 - Eml4-alk fusion gene: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, and a therapeutic agent for cancer.... Agent: Sughrue Mion, PLLC

20090099194 - Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders: The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors or for the treatment of viral infections. The compounds provided interfere with the binding of SDF 1 to the... Agent: King & Spalding

20090099195 - Therapeutic compounds 570: e

20090099196 - Chemical process: The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermediates useful in the manufacture of that compound and to processes for the manufacture of those intermediates. The invention also relates to particular crystalline forms of that compound such... Agent: Morgan Lewis & Bockius LLP

20090099197 - Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof: The invention described herein relates to diagnostic and treatment methods and compositions useful in the management of disorders, for example cancers, involving cells that overexpress MDR-1, and methods of decreasing the incidence of CNS complications that are often associated with CML patients that have been administered imatinib or other protein... Agent: Louis J. Wille Bristol-myers Squibb Company

20090099198 - Compounds, compositions and methods: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090099199 - Organic compounds: r

20090099200 - Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Azacyclohexane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis; obesity; diabetes;... Agent: Merck And Co., Inc

20090099201 - Diacylglycerol acyltransferase inhibitors: a

20090099202 - External preparation for athlete's foot treatment: External preparations for athlete's foot treatment capable of enhancing patient's compliance and capable of reducing the symptom of rubefaction, comprising an anti-trichophyton drug mixed with at least one compound selected from among 1-menthol, menthol analogue compounds and bactericidal compounds.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20090099203 - Composition 064: A pharmaceutical composition which comprises N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide with mannitol and/or microcrystalline cellulose is described.... Agent: Astrazeneca R&d Boston

20090099204 - Amide derivative, insecticide containing the same and method for application thereof as insecticide: wherein, in the formula, A1, A2, A3 and A4 each represent a carbon atom or the like; R1 and R2 are each a hydrogen atom, an alkyl group or the like; G1 and G2 are each an oxygen atom or the like; X represents a hydrogen atom, a halogen atom... Agent: Buchanan, Ingersoll & Rooney PC

20090099205 - Chemokine receptor binding compounds: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).... Agent: Morrison & Foerster LLP

20090099209 - Compounds useful in therapy: e

20090099207 - Cyclic sulfones useful as bace inhibitors:

20090099208 - Novel guanidine derivatives and their medical use: This invention relates to novel guanidine derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20090099206 - Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use: Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3′-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and salts thereof are disclosed.... Agent: Lexicon Pharmaceuticals, Inc.

20090099210 - Enantiomers of selected fused heterocyclics and uses thereof: l

20090099211 - Treatments for congestive heart failure: Methods and pharmaceutical preparations for treating heart failure by administering to a human or animal subject a therapeutically effective amount of at least one substance selected from the group consisting of a) SOD mimics (e.g., Tempol), b) NADPH oxidase inhibitors (e.g., Apocynin) and c) other substance that inhibit or reduce... Agent: Ice Miller LLP

20090099212 - A3 adenosine receptor antagonists: wherein R is hydrogen or acyl; R1 is hydrogen, halo, optionally substituted C1-4 alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl; R2 is optionally substituted C1-4 alkyl; Y is C1-4 alkylene; and Z is phenyl, optionally substituted with halo, optionally substituted C1-4 alkyl, or C1-4 alkoxy. The... Agent: Cv Therapeutics, Inc.

20090099214 - Organic compounds: e

20090099213 - Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors: The invention provides a compound for use in the prophylaxis or treatment of a disease state or condition mediated by protein kinase B, the compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N═C(R6), (R7)C═N, (R8)N—C(O), (R8)2C—C(O), N═N or... Agent: Heslin Rothenberg Farley & Mesiti PC

20090099215 - Metabolic enhancing properties of norphenephrine and its salts: Norphenephrine and its salts are disclosed which have powerful metabolic enhancing effects in humans via oral administration. The metabolic enhancing properties include positive blood sugar regulation, increased thermogenesis and fat loss, increased anticatabolism/anabolism, decreased appetite, improved mental focus and psychological outlook and increased energy production and anti-fatigue actions.... Agent: Darby & Darby (formerly Michael J. Keller)

20090099216 - Novel adenine compound: wherein Z represents (un)substituted alkylene, a single bond, etc.; R1 represents an (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl group; R2 represents hydrogen or (un)substituted alkyl; R3, R4 and R5 each independently represents an (un)substituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl group, provided that R3 and R5 may be... Agent: Birch Stewart Kolasch & Birch

20090099217 - 2-aminopyrimidin-4-ones and their use for treating or preventing alpha beta-related pathologies: This invention relates to novel compounds having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Pepper Hamilton LLP

20090099218 - Synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (bpu) sulfur analogs: This invention provides a series of BPU analogues; their synthesis and evaluated biological activity. BPU sulfur analogues were found to possess up to 20 fold increased potency, when compared to compound 1, in various cancerous cell lines.... Agent: Pearl Cohen Zedek Latzer, LLP

20090099219 - Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same: in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, and salts, N-oxides, metabolites, solvates, tautomers and prodrugs thereof, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the... Agent: Millen, White, Zelano & Branigan, P.C.

20090099220 - Antimalarial compounds with flexible side-chains: The present invention relates to novel compounds that are inhibitors of wild type and mutant dihydrofolate reductase (DHFR) of Plasmodium falciparum, which are useful for the treatment of malaria. It also relates to processes of making and using such compounds. The antimalarial compounds of the present invention have low toxicity... Agent: Morrison & Foerster LLP

20090099221 - Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene-and furane-derivatives as kinase inhibitors: The present invention provides compounds of the formula (I), or the pharmaceutically acceptable salts thereof, wherein G, W, R2, R3, R4, R5 and R6 are as defined in the specification. Further objects of the invention are processes and intermediates for the preparation of the compounds of the formula (I), pharmaceutical... Agent: Scully Scott Murphy & Presser, PC

20090099223 - Methods of treating hormone-related conditions using thio-oxindole derivatives: e

20090099222 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Honigman Miller Schwartz & Cohn LLP

20090099224 - C7- substituted camptothecin analogs: The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug... Agent: Scott A. Whitaker, Ph.d., J.d. Senior Intellecual Property Counsel

20090099225 - Method for the production of propellant gas-free aerosols from aqueous medicament preparations: The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090099226 - Quinoline derivatives as ep4 antagonists: The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I): wherein A and B represents either a... Agent: Merck And Co., Inc

20090099227 - G-protein coupled receptor agonists: Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.... Agent: Osi Pharmaceuticals, Inc.

20090099228 - Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists: The invention relates to novel pyrazolo-tetrahydropyridines compounds and their use as orexin receptor antagonists.... Agent: Hoxie & Associates LLC

20090099229 - Isoquinolines as igf-1r inhibitors: e

20090099230 - Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide: Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide are described herein, including crystalline forms thereof.... Agent: Honigman Miller Schwartz & Cohn LLP

20090099231 - 3-sulfonylamino-pyrrolidine-2-one derivatives as factor xa inhibitors: The present invention provides pyrrolidinone derivatives as Factor Xa inhibitors and pharmaceutical compositions comprising the same. The invention also relates to processes for the preparation of such compounds, and the use of such compounds in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090099232 - Injectable depot formulation comprising crystals of iloperidone: An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with... Agent: Hoffman Warnick LLC

20090099233 - Heteroaryl amides useful as inhibitors of voltage-gated sodium channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20090099234 - 2-pyridinylcycloalkylcarboxamide derivatives as fungicides: e

20090099236 - 3-amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof:

20090099237 - Methods of treating inflammatory diseases: Methods relating to selective inhibitors of the casein kinase 1 isoforms that are useful for the treatment of inflammatory diseases are presented.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090099235 - Pyrazolopyrrolidines as inhibitors of gamma secretase: wherein A, Y, R1, R1a, R2, and R2a are as described in the specification. Compounds of Formula I are useful in treating and/or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of preparing compounds of Formula I, and methods... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090099238 - Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment: The present invention relates to the use of a pparα agonist to treat patients suffering from weight gain associated with a pparγ agonist treatment.... Agent: Antonelli, Terry, Stout & Kraus, LLP

20090099239 - Antiviral compounds and methods: The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals.... Agent: Craig J. Arnold Amster, Rothstein & Ebenstein LLP

20090099240 - Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity: Disclosed herein are methods for treating energy metabolism disorders by administering a composition containing a therapeutically effective amount of a fatty acid amide hydrolase inhibitor. The composition can also be administered to reduce body fat, body weight, or caloric intake.... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090099241 - Pharmaceutical composition containing antihypertensive agents: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.... Agent: Novartis Corporate Intellectual Property

20090099242 - Heterocyclic inhibitors of necroptosis: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features... Agent: Clark & Elbing LLP

20090099243 - Organic compounds: e

20090099244 - Organic compounds:

20090099245 - 2-{(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1: 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090099246 - 2-{(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2: 2-((R)-2-Methylpyrrolidin-2-yl)- I H-benzimidazole-4-carboxamide Crystalline Form 2, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090099247 - Use of tetramic acid derivatives for controlling pets by drenching, drip application, dip application or soil injection: Compounds of the formula (I) in which A, B, G, W, X, Y and Z can have the meanings given in the description are highly suitable for controlling animal pests such as insects and/or spider mites and/or nematodes by treating the soil/growth substrate by drenching or drip application or dipping... Agent: Bayer Cropscience Lp

20090099248 - Inhibitors of d-amino acid oxidase: The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or... Agent: Morgan, Lewis & Bockius LLP (sf)

20090099249 - Therapeutic lactams: e

20090099250 - Benzocycloheptene derivatives as estrogens having selective activity:

20090099251 - Dietary and pharmaceutical compositions containing tricyclic diterpenes and their derivatives and their uses: The present invention refers to tricyclic diterpenes and their derivatives of the formulae (I) and (II), wherein R1 is hydrogen or C1-6-alkyl; R2 is hydroxy, C3-5-acyloxy, hydroxymethyl, 1,3-dihydroxypropyl or C1-6-alkyl; R3 and R4 independently from each other are hydrogen, hydroxy, hydroxymethyl, C1-5-acyloxy or C1-6-alkoxy; R5 is C1-6-alkyl, hydroxymethyl carboxy or... Agent: Nixon & Vanderhye, PC

20090099252 - Novel laulimalide analogues as therapeutic agents: Laulimalide analogues useful as microtubule stabilizing agents, and in the treatment of abnormal cell proliferation, are disclosed. Methods of making the compounds, as well as methods of using such compounds in treating abnormal cell proliferation diseases are also described.... Agent: King & Spalding

20090099253 - Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use: Internally masked neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090099254 - Method and kit for regulation of microvascular tone: Methods and kits for regulating arterial microvascular tone in which a composition comprising a COX-2 inhibitor and a cannabinoid receptor agonist are administered to a subject.... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20090099255 - Agent for alleviating vascular failure: [Means to solve] It is possible to provide an agent for alleviating, treating and preventing vascular failure and a vascular endothelial cell-protecting agent characterized by containing, as an effective ingredient, at least one active oxygen scavenger such as astaxanthin and tocotrienols; and a food, a drink and an animal feed... Agent: Flynn Thiel Boutell & Tanis, P.C.

20090099256 - Drug for treating circulatory insufficiency: and/or a physiologically acceptable salt thereof as an active ingredient, wherein R1 is an alkyl group having 1 to 10 carbon atoms, or an alkenyl group having 2 to 10 carbon atoms; and any one of R2, R3, R4 and R5 is a hydroxyl group, an alkoxy group, an alkenyloxy... Agent: Kratz, Quintos & Hanson, LLP

20090099257 - Composition and process for treating acne: A composition and process is disclosed for treating an acne infection with a composition of electrolytically generated silver citrate. The composition of electrolytically generated silver citrate may be applied topically to the acne infection in an aqueous solution or may be incorporated within a cosmetic product. The acne composition may... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090099258 - Physiological coolants based on lactoyl esters of menthyl lactate: A method of imparting a physiological cooling effect to a consumer product is disclosed. The method comprises formulating into the consumer product a composition comprising at least one lactoyl ester of menthyl lactate. Also disclosed is a method of providing physiological cooling by contacting skin or mucous membranes with the... Agent: Lyondellbasell Industries

20090099259 - Method for regulating gene expression: The present invention is directed to a novel method for modulating the expression of one or more genes in a subject by administering an amount of DHA and ARA to the subject.... Agent: Richard D. Schmidt Bristol-myers Squibb Company

20090099261 - Omega-3 mixtures: The present invention is directed to mixtures of omega-3 fatty acids, formulations of these mixtures suitable for use in a variety of dosage forms or food/beverage additives, and uses of these mixtures for preventative or therapeutic health purposes.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090099260 - Polyunsaturated fatty acid-containing solid fat compositions and uses and production thereof: The present invention provides a solid fat composition that includes an oil having saturated fat and an oil having at least one long chain polyunsaturated fatty acid. In particular, the solid fat composition can have high levels of long chain polyunsaturated fatty acid and low to no presence of emulsifiers.... Agent: Sheridan Ross P.C.

20090099262 - Methods and compositions for the management of soil borne fungal diseases: Improved methods and compositions for protecting plants or seeds from soil-borne fungal diseases. The composition may include a triterpenoid isolated from Glycyrrhiza glabra and a polymer. The triterpenoid may be Carbenoxolone disodium salt, and the polymer may be a water-insoluble, water-soluble or flowable, seed coating polymer. The methods may comprise... Agent: Head, Johnson & Kachigian

20090099263 - Organ-adhesion preventing agent and process for preventing adhesion using thereof: There is disclosed an organ-adhesion preventing agent comprising a chemically-crosslinked γ-polyglutamic acid as an effective ingredient, as well as a process for preventing organ from adhesion comprising a step of bringing the adhesion-preventing agent into contact with or depositing the same onto the surface of a local organ and optionally... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090099264 - Fluoroalkylamine derivatives as cathepsin inhibtors: The present invention provides compounds of formula I which are inhibitors of cathepsin S and as such are useful in the prevention and treatment of cathepsin S dependent diseases and conditions including, but not limited to, chronic obstructive pulmonary disease (COPD) and pain.... Agent: Merck And Co., Inc

20090099265 - Trans-clomiphene for metabolic syndrome: The present invention relates to the administration of compositions comprising an antiestrogen, preferably trans-clomiphene, for treating metabolic syndrome in a subject. The invention is also directed to methods for reducing fasting glucose levels in a subject by administering a composition comprising an antiestrogen, preferably trans-clomiphene.... Agent: Howrey LLP - East

20090099266 - Antifungal nail coat and method of use: Antifungal nail coat compositions containing an allylamine, an N,N-di(C1-C8) alkylamino substituted, (C4-C18) alkyl (C2-C18) carboxylic ester or a pharmaceutically acceptable acid addition salt thereof, a hydrophilic polymer, and a pharmaceutically acceptable, volatile organic carrier are disclosed. The composition provides a substantially water-soluble, fungicidal coating upon contact with a fungally susceptible... Agent: Olson & Cepuritis, Ltd.

20090099267 - Polymers, compositions and methods of making the same: Polymers having a main chain having both aromatic units and aliphatic units (with repeating heteroatoms) and a side chain macromonomer are described. Methods of making these polymers using enzymatic synthesis and the applications of these polymers are also described.... Agent: Fish & Richardson PC

20090099268 - Anti-adhesion membrane: l

  
04/09/2009 > patent applications in patent subcategories. category listing, related patent applications

20090093396 - Diagnostics and therapeutics for restenosis: Methods and kits for determining whether a subject has or is predisposed to developing restenosis are provided.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090093395 - Method for determining predisposition to pulmonary infection: Provided herein are methods and materials for diagnosing a subject's predisposition for pulmonary infection in a CF subject by detecting a pulmonary infection genetic marker. Pulmonary infection markers have been identified in the IL-1 gene cluster and may be useful in predicting CF disease progression and assessing a CF subject's... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20090093397 - Phaseolus vulgaris extracts, their use, and formulations containing them: Extracts obtainable by extraction from Phaseolus sp. with aqueous solutions, characterised by an α-amylase inhibitor content with an activity equal to or greater than 1,800 USP/mg (HPLC titre equal to or greater than 15% w/w) and a phytohaemagglutinin content of between 1,500 and 6,000 HAU/g, and a process for its... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090093404 - Accelerated angiogenesis-inducing protein, compositions inducing accelerated angiogenesis and uses thereof: The present invention refers to an angiogenesis-inducing protein, a composition containing it and the uses of said protein.... Agent: Fitch Even Tabin And Flannery

20090093402 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090093401 - Cystatin c as an antagonist of tgf-beta and methods related thereto: Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of... Agent: Sheridan Ross PC

20090093399 - Glycopegylation methods and proteins/peptides produced by the methods: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.... Agent: Morgan, Lewis & Bockius LLP (sf)

20090093411 - Long-acting hormone and growth factor compositions and uses thereof: This invention provides VEGF-FSH compounds having increased serum half-lives relative to either native VEGF or FSH, in which both VEGF and FSH are biologically active. This invention also provides related compositions and methods for increasing fertility, egg production and spermatogenesis in a subject, as well as methods for increasing vascularization... Agent: Cooper & Dunham, LLP

20090093407 - Matrix-targeted fusion polypeptides for tissue regeneration and wound healing: The present invention relates to compositions and methods for promoting tissue repair and regeneration. The invention provides a fusion polypeptide useful for targeting tissues for regeneration and methods of use therefore.... Agent: Fish & Richardson, PC

20090093410 - Methods for local treatment with factor vii: The present invention provides methods for the local treatment of bleeding in a subject and/or reducing unwanted effects associated with the systemic administration of thrombotic agents to a subject, by local administration of FVII to the subject.... Agent: Licata & Tyrrell P.C.

20090093412 - Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections: Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with a colony stimulating factor (CSF)... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090093413 - Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections: Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with a colony stimulating factor (CSF)... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090093409 - Neuroprotective synergy of erythropoietin and insulin-like growth factors: The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time... Agent: Mcdermott, Will & Emery

20090093405 - Non-natural amino acid polypeptides having modified immunogenicity: Non-naturally encoded amino acid polypeptides with modulated immunogenicity and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20090093408 - Protection of exendin-4 peptides through conjugation: A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide... Agent: Jones Day

20090093403 - Systems, methods and compositions for optical stimulation of target cells: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated NpHR-based molecule comprising a nucleic acid sequence that codes for light-activated NpHR-based molecule and a promoter. Either a high expression... Agent: Crawford Maunu PLLC

20090093400 - Truncated keratinocyte growth factor (kgf) having increased biological activity: The present invention relates to a keratinocyte growth factor fragment, KGFdes1-23, or an analog thereof that is composed of a portion of an amino acid sequence of mature, full length keratinocyte growth factor, KGF163. The fragment exhibits at least a 2-fold increase in mitogenic activity as compared to a mature,... Agent: Novartis Vaccines And Diagnostics Inc.

20090093398 - Use of fibroblast growth factor fragments: A discovery process beginning with an in vivo screening of proteins, peptides, natural products, classical medicinal compound or other substances. The administration of compounds to the animal can be either direct or indirect, such as by the administration and expression of cDNA-containing plasmids. Since the discovery process of the invention... Agent: Novartis Institutes For Biomedical Research, Inc.

20090093406 - Vegetable protein concentrate having a reduced insoluble dietary fiber content and increase amount of soluble dietary fiber content: d

20090093414 - Hyaluronic acid-methotrexate conjugate: An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint disorders. There is provided a hyaluronic acid-methotrexate conjugate useful for the treatment of joint disorders, wherein methotrexate is conjugated with a hydroxy group of hyaluronic acid through a linker containing... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090093415 - Therapeutic agent for irritable bowel syndrome: [Means for Resolution]It was shown that the bombesin 2 (BB2) receptor antagonists typified by RC-3095 are therapeutic agents for irritable bowel syndrome (IBS), which show excellent efficacy in both of an abdominal symptom and bowel movement disorder. Thus, according to the present invention, it became possible to provide a therapeutic... Agent: Fitzpatrick Cella Harper & Scinto

20090093416 - Caspase inhibitors and uses thereof: e

20090093417 - Dual-acting antihypertensive agents: wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates... Agent: Theravance, Inc.

20090093418 - Novel aminoglycosides and uses thereof in the treatment of genetic disorders: A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090093419 - Glucopyranosyloxypyrazole derivatives and use thereof in medicines: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom;... Agent: Sughrue Mion, PLLC

20090093420 - Processes for the preparation of azithromycin: The invention relates to processes for the preparation of anhydrous azithromycin. The invention also relates to a one-pot process for the preparation of azithromycin without isolation of intermediates. The invention also relates to pharmaceutical compositions that include the anhydrous azithromycin or a pharmaceutically acceptable salt thereof.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090093421 - Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20090093422 - Oxazolidinone derivatives and methods of use: This invention relates to novel N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide derivatives, their acceptable acid addition salts, solvates and hydrates. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antimicrobial agents.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090093427 - Articular cartilage gene therapy with recombinant vector encoding bmp-7: The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of osteoarthritis in mammals, advantageously in humans, dogs, horses and cats, by intra-articular administration of the recombinant vectors and... Agent: Judy Jarecki-black Ph.d., J.d.

20090093430 - Biomarkers and methods for identification of agents useful in the treatment of affective disorders: Potential therapeutic, agent for the prevention, treatment or amelioration of an affective disorder, such as a bipolar disorder, depression or anxiety disorder are identified. Also provided are methods for diagnosing and monitoring affective disorders. The methods are based on changes in expression of one or more genes that are differentially... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090093429 - Combination therapy for treating cancer: The invention relates to treatment of primary and secondary tumors using a therapeutic combination including ionizing radiation and gene therapy comprising mutant-LIGHT. Methods of treating a tumor and inducing an anti-tumor immune response are also provided.... Agent: Michael Best & Friedrich LLP

20090093424 - Markers for melanoma: A method of diagnosing melanoma and/or monitoring melanoma progression, in particular for determining whether the melanoma is likely to have metastatic capabilities, in a subject includes the steps of in a test sample determining the methylation status of FABP5 wherein methylation of the gene indicates a positive diagnosis of melanoma... Agent: Foley And Lardner LLP Suite 500

20090093428 - Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis: Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090093437 - Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating checkpoint kinase (e.g., checkpoint kinase-1 or CHK-1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of... Agent: Sirna Therapeutics, Inc.

20090093439 - Rna interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating chromosomal translocation gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of chromosomal translocation gene expression and/or... Agent: Sirna Therapeutics, Inc.

20090093435 - Rna interference mediated inhibition of grb2 associated binding protein (gab2) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of associated binding protein... Agent: Sirna Therapeutics, Inc.

20090093431 - Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering nucleic acid (sina): This inventon relates to compounds, compositions, and methods useful for modulating NOGO and/or NOGO receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of NOGO and/or NOGO... Agent: Sirna Therapeutics, Inc.

20090093436 - Rna interference mediated inhibition of vascular cell adhesion molecule (vcam) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating vascular cell adhesion molecule gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of vascular cell adhesion... Agent: Sirna Therapeutics, Inc.

20090093438 - Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating XIAP gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of XIAP gene expression and/or activity by... Agent: Sirna Therapeutics, Inc.

20090093426 - Rnai modulation of scap and therapeutic uses thereof: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a... Agent: Alnylam/fenwick

20090093433 - Sense mrna therapy: The present invention describes novel methods for the stabilization of mRNA. These alterations increase stability of mRNA and enable its use in sense RNA therapy to transiantly express proteins in a cell. Accordingly, the present invention is directed to methods for making such modifications, compositions comprising such modifications, and the... Agent: Invitrogen Corporation C/o Intellevate

20090093425 - Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups: This disclosure relates to nucleic acid constructs modified to have a reduced net anionic charge. In some aspects the constructs comprise phosphodiester and/or phosphothioate protecting groups. The disclosure also provide methods of making and using such constructs.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20090093432 - Tumor inhibition by modulating sprouty expression or activity: Methods are provided for identifying compounds that decrease the expression or activity of an overexpressed Sprouty protein in certain cancers. Such compounds can be useful for treating cancers in which a Sprouty protein is overexpressed. Also provided are therapeutic formulations and pharmaceutical formulations for treating cancers characterized by overexpression of... Agent: Wilmerhale/boston

20090093434 - Use of eif-5a1 sirna to protect islets cells from apoptosis and to preserve their functionality: The present invention relates to methods for improving the viability, recovery and functionality of islets that are separated from a donor organ for subsequent transplantation and more particularly relates to the use of eIF-5A1 siRNAs to enhance the viability and functionality of islets.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090093440 - Fragranced therapeutic delivery system: The present invention relates to multi-functional topical delivery systems for providing long-lasting delivery of fragrance as. well as skin-supporting and/or pharmaceutically active ingredients comprising (i) an oil phase; (ii) an aqueous phase; (iii) phenoxyethanol at a concentration of from about 2.0% to about 2.7% based on the total weight of... Agent: Louis C. Paul

20090093441 - Preventing or reducing oxidative stress or oxidative cell injury: A water-insoluble cellulose derivative, such as ethyl cellulose is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for influencing the level Stearoyl-CoA Desaturase-1 (SCD1) gene expression or ATP synthase mitochondrial F1 complex assembly factor 1 (ATPAF1) gene expression in... Agent: The Dow Chemical Company

20090093442 - Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome: Water-soluble cellulose derivatives are useful in methods of preventing or treating metabolic syndrome or a symptom or condition associated with the metabolic syndrome in an individual, and in particular for preventing or treating one or more of the symptoms a) hypertension, b) proinflammatory or inflammation state and c) prothrombotic state.... Agent: The Dow Chemical Company

20090093443 - Combinations of 4- bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1h-pyrrole-3-carbonitrile and biocidal compounds: The present invention relates to combinations of 4-bromo-2-(4-chloro-phenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, and a biocidal compound which provide an improved protecting effect against fouling organisms. More particularly, the present invention relates to compositions comprising a combination of 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, together with one or more biocidal compounds selected... Agent: Philip S. Johnson Johnson & Johnson

20090093423 - Oxazolidinone derivatives and methods of use: wherein A=C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion, or —COOR4 where R4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable salt; R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, alkyl, protected amino, optionally substituted... Agent: Oliff & Berridge, PLC.

20090093444 - Cathepsin cysteine protease inhibitors: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.... Agent: Merck And Co., Inc

20090093445 - Release reagent for vitamin d compounds: The present invention concerns a reagent composition for releasing vitamin D compounds bound to vitamin D-binding protein, a method for the detection of a 25-hydroxyvitamin D compound in which the 25-hydroxyvitamin D compound is released from vitamin D-binding protein using this reagent and the mixture obtained in this manner is... Agent: Roche Diagnostics Operations Inc.

20090093447 - Cddo-compounds and combination therapies thereof: CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.... Agent: Fulbright & Jaworski L.L.P.

20090093446 - Method for alleviating keratoconjunctivitis sicca: An improved method of increasing tear production is by intranasally administering a therapeutically effective amount of a capsaicinoid compound to patients with deficient tear production. Optional incorporation into the intranasal formulation of a topical corticosteroid or topical anesthetic compound is used to reduce transient nasal stinging and burning which may... Agent: Barnes & Thornburg LLP

20090093448 - 19-nor-progesterone for contraception:

20090093449 - Concentrated aqueous azalide formulations: The present invention relates to formulations of concentrated azalide antibiotics and methods for making and using them. Specifically, the invention relates to a method of treating an infection comprising administering to a patient in need thereof, an effective amount of a concentrated aqueous azalide antibiotic formulation made according to the... Agent: Mcdermott Will & Emery LLP

20090093450 - Agent for inhibiting visceral fat accumulation: To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity, considered to be a main factor of metabolic syndrome, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent... Agent: Knobbe Martens Olson & Bear LLP

20090093451 - Il-8 receptor antagonists: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090093452 - Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives: wherein RQ, R7, n, Q2, Q3, Y, and X1-X3 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and... Agent: Pfizer Inc

20090093453 - Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof: wherein R1 and R2 independently represent at least one group selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an alkenyl group, an alkenyloxy group, an amino group, an alkylsulfonyl... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090093454 - Chemical compounds: e

20090093456 - Novel mch receptor antagonists: The present invention relates to a melanin concentrating hormone antagonist compound of formula (1): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.... Agent: Eli Lilly & Company

20090093455 - Quinolone analogs and methods related thereto: The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.... Agent: Morrison & Foerster LLP

20090093457 - Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions: e

20090093459 - 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof: The present invention relates to 2-alkoxy-3,4,5-trihydroxyalkylamide benzothiazepine compounds, to pharmaceutical compositions comprising such compounds, to methods of treatment comprising administering such compounds, to processes for the preparation of such compounds and to intermediate precursors to such compounds.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090093458 - Methods of identifying anti-cancer agents and uses thereof: The present invention provides methods of identifying and/or detecting anti-cancer agents. The present invention provides methods of identifying and/or detecting compounds that can activate PARP and/or induce necrosis. The present invention also provides for methods of treating cancer in an individual. The present invention also provides kits for identifying and/or... Agent: Pepper Hamilton LLP

20090093460 - Compositions: Pharmaceutical compositions, oral pharmaceutical compositions, and solid dosage forms comprising up to about 750 mg of 11-piperazin-1-yldibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent are provided.... Agent: Pepper Hamilton LLP

20090093461 - Methods of treating anxiety and mood disorders: a

20090093462 - 3-arylamino pyridine derivatives: The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090093464 - Naphthalene derivatives as modulators of the glucocorticoid receptor: The present invention relates to naphthalene derivatives of formula (I) that are modulators of the glucocorticoid receptor, and to processes for the preparation and use of the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090093463 - Novel compounds of substituted and unsubtituted adamantyl amides: The present invention relates to compounds with the formula (I) or a pharmaceutically acceptable salt thereof: The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of 11-β-hsd-1, the method comprising administering to a mammal... Agent: Pfizer Inc

20090093465 - Therapeutic kinase modulators: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, and modulating protein kinase activity. Molecules of the invention can modulate casein kinase (CK) activity. The invention also relates in part to methods for using such molecules.... Agent: Morrison & Foerster LLP

20090093466 - Carboxamide gabaa alpha2 modulators: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090093467 - Therapeutic compositions and methods: The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof.... Agent: Viksnins Harris & Padys Pllp

20090093468 - Peptide deformylase inhibitors: Benzothiazine compounds of the general formula (I) and pharmaceutically acceptable salts or esters thereof are peptide deformylase inhibitors useful in the treatment or prevention of infections and other diseases in which peptide deformylases are involved, especially in the treatment of bacterial and parasitic infections, for example infections fully or partly... Agent: Edwards Angell Palmer & Dodge LLP

20090093469 - Phenylaminopropanol derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly... Agent: Woodcock Washburn LLP/wyeth

20090093470 - Photodynamic therapy process and photosensitizer compositions therefor: A process of performing photodynamic therapy is provided along with a photosensitizer composition suitable for the process. The photosensitizer composition comprises at least one photoactive ingredient in a chemically reduced state. According to the process, the photosensitizer composition having at least one photoactive ingredient in a chemically reduced state is... Agent: Dobrusin & Thennisch PC

20090093471 - Methods of treating nervous disorders: The invention relates to compositions and methods for treating nervous disorders. More particularly, the invention relates to methods of treating amyloÊd beta peptide-related disorders, particularly Alzheimer's disease, using Rac1 inhibitors. The invention may be used in mammalian subjects, particularly human subjects, at various stages of the disease, including disease onset.... Agent: Nixon & Vanderhye, PC

20090093472 - Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation: e

20090093473 - Spiro-benzimidazoles as inhibitors of gastric acid secretion:

20090093474 - Thiazolyl-dihydro-indazole:

20090093475 - Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals:

20090093476 - Pyrrolo[1,2-a]quinoxaline derivatives as adenosine a3 receptor modulators and uses thereof: The present invention provides new compounds displaying high affinity for adenosine A3 receptors. It also provides modulators of adenosine A3 receptors. It further provides compounds for the treatment and/or prophylaxis of conditions and diseases where adenosine A3 receptor plays a role. Pharmaceutical compositions for the treatment and/or prophylaxis of conditions... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090093477 - Tetrahydropyrrolopyrimidinediones and their use in therapy: —[X]m-[Alk1]p-[Q]n-[Alk2]q-[X1]k-Z wherein k, m, n, p and q are independently 0 or 1; Alk1 and Alk2 each independently represent an optionally substituted C1-C6 alkylene, or C2-C6 alkenylene radical which may optionally contain an ether (O—), thioether (—S—) or amino (—NRA—) link wherein RA is hydrogen or C1-C3 alkyl; Q represents... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090093478 - N-aroyl cyclic amines: x

20090093479 - Anti-cancer agents and uses thereof: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring... Agent: Pepper Hamilton LLP

20090093480 - Insecticidal pyrimidinyl aryl hyrdrazones: Pyrimidinyl aryl hydrazones are effective at controlling insects.... Agent: Dow Agrosciences LLC

20090093481 - Insecticidal (1,3,5)-triazinyl phenyl hydrazones: (1,3,5)-Triazinyl phenyl hydrazones are effective at controlling insects.... Agent: Dow Agrosciences LLC

20090093482 - Therapeutic compositions and methods: The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof.... Agent: Viksnins Harris & Padys Pllp

20090093483 - Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof: e

20090093484 - Novel compounds, their preparation and use: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPARδ and should be useful for treating conditions mediated by the same.... Agent: High Point Pharmaceuticals, Inc.

20090093487 - Compositions for topical application having androgenic actions: v

20090093486 - Insecticidal substituted azinyl derivatives: N-Azinyl-N′-aryl ureas and thioureas derivatives are effective at controlling insects.... Agent: Dow Agrosciences LLC

20090093485 - Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases: Compounds of formula (I) or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).... Agent: Fish & Richardson P.C.

20090093488 - Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an... Agent: Osi Pharmaceuticals, Inc.

20090093489 - Novel compounds for treatment of cancer and disorders associated with angiogenesis function: Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian... Agent: Hogan & Hartson L.L.P.

20090093491 - Diazine azole derivatives, their manufacture and use as pharmaceutical: v

20090093490 - Heterocyclylethylbenzamide derivatives:

20090093492 - Il-8 receptor antagonists: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090093493 - 1-phenylalcoxy-2-beta-phenylethyl derivatives as p-glycoprotein (p-gp) inhibitors useful in drug resistance events: The invention relates to a new class of compounds, which are 1-phenylalcoxy-2-β-phenylethyl derivatives, as P-glycoprotein (P-GP) inhibitors. These compounds are useful in drug resistance events. They have been shown able to inhibit in a dose-dependent manner Glycoprotein-P (P-gp) activity in cell lines in which the expression of said glycoprotein is... Agent: Joseph Fischer, Esquire Beusse Wolter Sanks Mora & Maire, P.A.

20090093494 - 4-pyrimidineamine compounds and uses as anti-proliferative agents: The present disclosure provides 4-pyrimidineamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090093495 - Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases: A combination and methods are disclosed which are useful for the treatment of cancer and/or leukemia.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090093496 - Preparation of pharmaceutical salts of piperazine compounds: The present invention is generally directed to a process to directly prepare pharmaceutically acceptable salts enriched with respect to selected rotameric salts of a basic compound, by creative choice of an acid and a solvent medium. The process is particularly useful in preparing specific rotamers of pharmaceutically useful salts in... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090093497 - Diacylglycerol acyltransferase inhibitors: e

20090093498 - Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient.... Agent: Wyeth Patent Law Group

20090093501 - Heterocyclic antiviral compounds: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3, R4 and Y are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present... Agent: Grant D. Green Roche Palo Alto LLC

20090093500 - Pesticidal compositions: The invention disclosed in this document is related to field of pesticides and their use in controlling pests.... Agent: Dow Agrosciences LLC

20090093499 - Pharmaceutical composition: A chemically stable formulation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically-acceptable salt thereof for oral use, such as tablets, capsules, powders, granules has been developed using the substances which stabilize against formation of degradation products: lactone and oxidation product.... Agent: Sandoz Inc

20090093502 - Energy status of an individual by enhanced usage of an endogenous fuel source: The present invention relates to a method of improving the energy status of an individual by enhancing the usage of lactate. Improved lactate usage is accomplished through a composition comprising lactate precursors, adrenergic receptor agonists and insulinotropic agents.... Agent: Torys LLP

20090093503 - Combinations comprising antimuscarinic agents and pde4 inhibitors: A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receplors which is (3R)-1-phencthyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octanc, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.... Agent: Hoxie & Associates LLC

20090093504 - 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same: Provided are quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.... Agent: Jones Day

20090093507 - Cdk inhibitors containing a zinc binding moiety: The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20090093506 - Copper antagonist compositions: Pharmaceutical compositions having a pharmaceutically acceptable copper antagonist compound(s) or a pharmaceutically acceptable salt or prodrug thereof, including copper (II) antagonists, and a pharmaceutically acceptable 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor or a pharmaceutically acceptable salt or prodrug thereof, articles and kits and delivery devices containing such compositions, tablets and capsules... Agent: Duane Morris LLP - San Diego

20090093505 - Imazalil compositions comprising alkoxylated amines: The present invention relates to the use of alkoxylated amines to enhance the activity of fungicidal formulations comprising the fungicidal compound imazalil. It also relates to formulations comprising imazalil and alkoxylated amines. These formulations are useful to protect materials, plants, fruits or seeds against fungi.... Agent: Philip S. Johnson Johnson & Johnson

20090093508 - Therapeutic or prophylactic agent for allergic dermatitis: A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to... Agent: Darby & Darby P.C.

20090093509 - Methods and compositions for the treatment of pruritus: The present invention is based on the discovery that a nalmefene salt or a peripherally acting analogue of nalmefene is capable of providing long-acting activity against pruritus, when applied topically. In addition, treatment with a nalmefene salt or peripherally acting analogue of nalmefene, can provide disease-modifying effects against the chronic... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090093511 - Mast cell stabilizers in the treatment of obesity: The present invention is directed to methods of treating or preventing the development of obesity by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing obesity.... Agent: Law Office Of Michael A. Sanzo, LLC

20090093510 - Use of nitrooxyderivatives of drug for the treatment of muscular dystrophies: The present invention relates to the use of nitric oxide releasing compounds for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.... Agent: Arent Fox LLP

20090093512 - 1, 2, 3, 3a, 8, 8a-hexahydro-2, 7a-diada-cyclopenta[a]inden-7-one derivatives which bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function and in the treatment of addictive disorders: The present invention relates to novel fused bicyclicpyrrolidine pyridone compounds of the formula (I) wherein R, RP and n are as defined herein, their pharmaceutically acceptable salts, pharmaceutical compositions and their use in treating addictive disorders such as the use of tobacco or other nicotine containing products and in the... Agent: Pfizer Inc Steve T. Zelson

20090093513 - Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter: The sponges were collected from a variety of locations in the Florida Keys and separated based on morphology and color. The samples were identified as three species, two of which are well known: V. rigida (Esper, 1794) (order Verongida, family Aplysinidae) and S. aurea (Hyatt, 1875) (order Dictyoceratida, family Thorectidae),... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090093514 - Immune response modifier formulations containing oleic acid and methods: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.... Agent: Edwards Angell Palmer & Dodge LLP

20090093515 - Substituted pyrroline kinase inhibitors: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.... Agent: Philip S. Johnson Johnson & Johnson

20090093516 - Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors: e

20090093517 - Bis1,2,3,4-tetrahydroisoquinoline derivatives and their uses as pharmaceuticals:

20090093518 - Piperidinyl-substituted isoquinolone derivatives:

20090093519 - Methods and compositions to inhibit edema factor and adenylyl cyclase: Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3′,5′-adenosine monophosphate. Specific compositions of the invention are also novel.... Agent: Fulbright & Jaworski, LLP

20090093520 - Plasma carboxypeptidase b inhibitors: a

20090093521 - 2, 5-bis-diamine [1,4] benzoquinone-derivatives: Synthesis of 2,5-bis-diamine-[1,4]benzoquinonic derivatives having the general formula (I), products and intermediates of said synthesis; the synthesis involves the use of p-benzoquinones having the general formula (IX) and diamines having the general formula (XI).... Agent: Marshall, Gerstein & Borun LLP

20090093522 - Freeze-dried pantoprazole preparation and pantoprazole injection: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.... Agent: Gary M. Nath The Nath Law Group

20090093524 - Compounds and methods for modulating fxr: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.... Agent: Eli Lilly & Company

20090093523 - Tetrazole-substituted aryl amide derivatives and uses thereof: m

20090093525 - Cyclopropyl aryl amide derivatives and uses thereof:

20090093526 - Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent: Millen, White, Zelano & Branigan, P.C.

20090093527 - Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Azacyclopentane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes;... Agent: Merck And Co., Inc

20090093528 - Methods for promoting composite tissue regeneration and uses thereof: The present invention provides a use and method for GM284 to promote the regeneration of a bodily structure, comprised of a composite tissue in a subject. Additionally, the present invention provides a use and method for GM284 to promote composite tissue regeneration in a subject. The present invention further provides... Agent: Global Patent Group - Glm

20090093529 - Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient: (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or its salt shows a potent bladder relaxation effect in “isolated rat bladder smooth muscle relaxation test”, dose-dependently lowers the contraction frequency of rhythmic bladder contractions in “rat rhythmic bladder contraction measurement test” and, moreover, prolongs the urination intervals in “urination functions measurement test on cyclophosphamide-induced overactive... Agent: Sughrue Mion, PLLC

20090093530 - (2r)-2-[4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them: The present invention relates to novel (2R)-2-phenylpropanamides bearing a 4-sulfonylamino substituent on the 4 position of the phenyl group and to pharmaceutical compositions containing them, which are used as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells, and which are useful in the treatment of various ELR+CXC chemokine-mediated disorders.... Agent: Abelman, Frayne & Schwab

20090093531 - Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making... Agent: Frost Brown Todd, LLC

20090093532 - Polymorphs and amorphous forms of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1h-pyrazole-3-carbonitrile: The present invention relates to novel crystalline polymorphs, solvate pseudomorphs and amorphous form of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile (fipronil). The present invention also provides methods for preparing the novel polymorphs, pseudomorphs and amorphous form, as well as insecticidal or pesticidal compositions comprising same, and methods of use thereof as pesticidal agents.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090093533 - Compounds and methods for inhibiting hepatitis c viral replication: Macrocyclic compounds having the structures described herein are useful for inhibiting replication of the hepatitis C virus (HCV). In preferred embodiments, the compounds are active against both the NS3 protease and the NS3 helicase of HCV.... Agent: Knobbe Martens Olson & Bear LLP

20090093535 - Method and composition for treating heart failure: A method and composition for treating, preventing or ameliorating heart failure, cardiac hypertrophy, and/or myocardial dysfunction includes administering a therapeutically effective amount of a HDAC inhibitor, such as phenylbutyrate, in combination with an ACE inhibitor, such as captopril.... Agent: Dinesh Agarwal, P.C.

20090093534 - Mu opioid receptor ligands: methods of use and synthesis: Novel compounds and compositions including those compounds, as well as methods of using and making the compounds are herein described. The compounds are useful in therapeutic applications, including modulation of disease or disease symptoms in a subject (e.g., mammal, human, dog, cat, horse). The compounds are useful as modulators of... Agent: Edwards Angell Palmer & Dodge LLP

20090093536 - Pharmaceutical composition comprising thiacremonone for preventing or treating cancer: The present invention relates to an anti-cancer composition, which comprises a sulfur-containing compound thiacremonone as an active ingredient. The active ingredient induces the death of cancer cells by apoptosis through the action of specific inhibition of the activity of NF-κB. The composition can be effectively used in the treatment or... Agent: The Rafferty Patent Law Firm

20090093537 - Extracts rich in proanthocyanidins and relating process of preparation: The present invention relates to extracts containing high amounts of proanthocyanidins and the relating process of preparation involving the use as starting reactants of crushed fruits, plants or already prepurified extracts rich in proanthocyanidins.... Agent: Abelman, Frayne & Schwab

20090093538 - Method for treating cancer: The invention relates to a method of treating cancer in a subject, comprising administering to the subject an anti-cancer therapy and a compound that increases the oxidative stress of the cancer cells and activates p38.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090093539 - Anti-angiogenic compositions and methods of use thereof: The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a tanshinone compound. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods of treating a... Agent: Bozicevic, Field & Francis LLP

20090093540 - Anti-tumor composition: The present invention provides compositions having, as active ingredients, a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090093541 - Melanin eliminator preparation: e

20090093542 - Copper antagonist compositions: Pharmaceutical compositions having a pharmaceutically acceptable copper antagonist(s) or a pharmaceutically acceptable salts or prodrugs thereof, including copper (II) antagonists, and a pharmaceutically acceptable antihypertensive agent or a pharmaceutically acceptable salt or prodrug thereof, articles and kits and delivery devices containing compositions, tablets and capsules and formulations containing such compositions,... Agent: Duane Morris LLP - San Diego

20090093543 - Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production: Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 50 weight percent of eicosapentaenoic acid [“EPA”], an ω-3 polyunsaturated fatty acid, in the total oil fraction are described. These strains over-express heterologous Δ9 elongases, Δ8 desaturases, Δ5 desaturases, Δ17 desaturases, Δ12 desaturases and C16/18 elongases, and... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090093544 - Insecticidal compositions having improved effect: The present invention relates to the increase of the action of crop protection agents containing certain phthalic acid diamides by the addition of ammonium salts and/or phosphonium salts or by the addition of ammonium or phosphonium salts and penetration promoters, the corresponding agents, processes for their preparation and their use... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090093546 - Method and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using rxr modulators: Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds that are modulators of Retinoid X Receptors are provide.... Agent: Fish & Richardson, PC

20090093545 - Phenoxyalkycarboxylic acid derivatives in the treatment of irritable bowel syndrome or ulcerative colitis: A method of treating irritable bowel syndrome, ulcerative colitis, and other inflammatory conditions, comprising: administering to a patient in need thereof an effective amount of a compound selected from compound 1, its metabolite 2 and pharmaceutically acceptable salts or prodrugs thereof:... Agent: Foley And Lardner LLP Suite 500

20090093547 - Compositions and methods for treating premature ejaculation: Compositions and methods for the treatment of premature ejaculation have been developed. It has been discovered that premature ejaculation can be treated by administering a local anesthetic to the glans penis. The local anesthetic may be formulated as an emulsion, lotion, paste, gel, cream, ointment, shea butter, suspension, solution, balm,... Agent: Pabst Patent Group LLP

20090093548 - Colchine compositions and methods: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.... Agent: Cantor Colburn, LLP

20090093549 - Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses: The present invention provides aqueous pharmaceutical compositions containing a lipophilic therapeutic agent. In particular, the invention provides aqueous pharmaceutical compositions containing the compound 2,6-diisopropylphenol (propofol). Preferred compositions of the invention contain propofol in the presence of at least one block copolymer (for example, P188 or another poloxamer) and a polyethylene... Agent: Ratnerprestia-j&j

20090093550 - Biocompatible foams, systems, and methods: Biocompatible foams having excellent physical and chemical properties are described. The biocompatible foams can be formed in situ or applied as a pre-formed foam for the treatment of tissue. The invention provides biocompatible degradable foams formed with a poly-α(1→4)glucopyranose macromer. The invention also provides biostable foams formed with a poly(alkylene... Agent: Kagan Binder, PLLC

20090093551 - Remotely triggered release from heatable surfaces: The present invention provides particle conjugates for drug delivery. Such conjugates comprise one or more heatable surfaces, one or more thermally-responsive linkers, and one or more agents to be delivered. In some embodiments, conjugates and populations of conjugates can be used to treat and/or diagnose a disease, disorder, and/or condition.... Agent: Choate, Hall & Stewart LLP

20090093552 - Addition of lecithin as an antistatic agent for the crystallization processing of organic molecules: The present invention relates to the addition of lecithin during the crystallization of organic molecules in organic solvents as an antistatic agent to reduce or eliminate static buildup, thus reducing the potential for explosion and equipment damage during chemical processing.... Agent: Merck And Co., Inc

  
04/02/2009 > patent applications in patent subcategories. category listing, related patent applications

20090088367 - Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia: This invention relates to Applicant's discovery that Metabolic Syndrome, a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further... Agent: Catalyst Law Group, Apc

20090088368 - Compositions comprising them as ppar modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.... Agent: Genomics Institute Of The Novartis Research Foundation

20090088369 - Glp-1 and methods for treating diabetes: The present invention relates to use of GLP-1 or a related molecule having a GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a “drug holiday.” Practice of the invention... Agent: Clark & Elbing LLP

20090088371 - Combination therapy with syk kinase inhibitor: The invention encompasses methods of increasing platelet levels in a patient having or at risk for immune thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist, and methods of treating thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist to a patient in need... Agent: Rigel Pharmaceuticals Inc.

20090088373 - Use of compositions to enhance innate immune response: The present invention discloses methods of using of compounds for the enhancement of the innate immune system of a patient. In particular, the active compounds of the present invention include at least one calcineurin inhibitor, mTOR inhibitor or non-immunosuppresive derivative, or a derivative, isomer, or pharmaceutically acceptable salt thereof; and... Agent: Novartis Corporate Intellectual Property

20090088386 - Amyloid ß fibrillogenesis-inhibiting peptide: wherein X13, X14, and X15 are the same or different and each represents an α-amino acid, Z1 and Z2 are the same or different and each represents cysteine or serine, and when Z1 and Z2 represent cysteine, they may be crosslinked; and a pharmaceutical composition and an amyloid β fibrillogenesis... Agent: Foley And Lardner LLP Suite 500

20090088385 - Antibodies that bind to bgs-4: The present invention provides novel polynucleotides encoding BGS-4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides of the present invention. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-4 polypeptides to the... Agent: Louis J. Wille Bristol-myers Squibb Company

20090088381 - Compositions containing anti-hiv peptides and methods for use: Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen (SEQ ID NO:1) are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ... Agent: Mccarter & English LLP Cityplace I

20090088382 - Use of the cathelicidin ll-37 and derivatives therof for wound healing: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by... Agent: Birch Stewart Kolasch & Birch

20090088387 - Composition for long-acting peptide analogs: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide, wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group... Agent: Wilson Sonsini Goodrich And Rosati / Pharmain Ltd

20090088389 - Novel x-conotoxin peptides (-ii): An isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit neuronal amine transporter comprising the following sequence of amino acids: Cys Cys Gly Tyr Lys Leu Cys Xaa5 Xaa6 Cys, SEQ ID NO: 3, where Xaa5 and Xaa6 are independently absent or represent any amino acid residue except... Agent: Scully Scott Murphy & Presser, PC

20090088388 - Peptides for use in treating obesity: Novel cyclic and linear peptides of the formula R1—X—X1—X2—X3—X4—X5—X6—X7—X8—X9—X10—X11—R2 are useful in the treatment of obesity are provided.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090088390 - Polypeptide: The present invention provides a polypeptide inducing the production of an antibody in permucosal administration in the presence of no immunological adjuvant, a composition containing the polypeptide, and use thereof. The present invention solves the above object by providing a polypeptide inserted with a cell attachment motif of a cell... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090088391 - Strains of lactobacillus helveticus which do not ferment lactose: The invention relates to novel strains of Lactobacillus helveticus. More specifically, the invention relates to strains of Lactobacillus helveticus having a lactose-negative phenotype and to the uses thereof in the agri-food industry. The invention also relates to a method for obtaining such strains of Lactobacillus helveticus.... Agent: Marshall, Gerstein & Borun LLP

20090088392 - Treatment of melanoma: An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090088394 - Methods and compositions for therapeutic treatment: Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular,... Agent: Wilson Sonsini Goodrich & Rosati

20090088393 - Methods and formulations for converting intravenous and injectable drugs into oral dosage forms: Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption.... Agent: Mckee, Voorhees & Sease, P.L.C

20090088395 - Clarithromycin or salt thereof for use in the treatment or prevention of pulmonary disease induced by destruction of pulmonary alveoli: For the purpose of treatment and/or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090088396 - Active substance combination for cosmetic preparations: A combination of active substances for cosmetic preparations contains hyaluronic acid and at least one of its derivatives. At least 10 percent by weight is used in long-chain form with a molecular weight of at least 1,000,000 daltons. At least 2 percent by weight is used in short-chain form with... Agent: Epstein Drangel Bazerman & James, LLP

20090088397 - Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus: A pharmaceutical composition comprising an effective amount of a compound of formulas (I-III) and a pharmaceutically acceptable carrier. Methods for treating a hepatitis virus in a patient comprising administering an effective amount of the compound of formulas (I-III) are also presented.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090088401 - In-situ cancer autovaccination with intratumoral stabilized dsrna viral mimic: An improved autovaccination method designed to prevent or treat various neoplastic diseases by inducing a systemic immune response against a tumor and its remote metastases, consisting of the induction of an immunogenic cell death in one or more targeted tumor sites with local radiation therapy, cryotherapy, heat, chemotherapy or various... Agent: Mr. Max Stuhl Oppenheimer

20090088402 - Novel agent for inducing apoptosis comprising msx1 or a gene encoding the same as an active ingredient: The present invention relates to a novel use of Msx1 protein or a nucleotide encoding the same for inducing apoptosis. The Msx1 of the present invention induces apoptosis through direct interaction with p53 via a homeodomain and such interaction leads to increased stability, and/or nuclear localization of p53 in cells.... Agent: Sheridan Ross PC

20090088400 - Prostaglandin e2 modulation and uses thereof: Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).... Agent: Goudreau Gage Dubuc

20090088398 - Recombinant adenoviral vectors and methods of use: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also... Agent: Townsend And Townsend And Crew, LLP

20090088399 - Use of light sensitive genes: The invention relates to the use of a light-gated ion channel for the manufacture of a medicament for the treatment of blindness and a method for expressing said cell specific fashion, e.g. in ON-bipolar cells, ON-ganglion cells, or AII amacrine cells.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090088403 - A3 adenosine receptors as targets for the modulation of central serotonergic signaling: The present invention relates to the use of adenosine type 3 receptor (A3R) modulators to modulate serotonin transporter (SERT) function in vivo. In particular, antagonists of A3R can be used to inhibit A3R-dependent upregulation of SERT, for example, as antidepressants.... Agent: Fulbright & Jaworski L.L.P.

20090088404 - Extended release pharmaceutical formulations of s-adenosylmethionine: Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to... Agent: Wilson Sonsini Goodrich & Rosati

20090088405 - Personal lubricants with built-in or accompanying odorant delivery systems: A personal lubricant paired with an odorant release device.... Agent: Tod R Nissle

20090088422 - 4-imidazolin-2-one compounds: wherein ring B is benzene ring which may be substituted, etc., Q1 and Q2 may be the same or different, and each is hydrogen atom, a halogen atom or an alkyl, n is 0, 1, 2, 3 or 4, R1 is hydrogen atom, an alkyl which may be substituted, a... Agent: Birch Stewart Kolasch & Birch

20090088423 - Methods and compositions for treating bacterial infections and diseases associated therewith: The invention features methods and compositions for treating bacterial infections.... Agent: Intellectual Property / Technology Law

20090088425 - Glucocorticoid receptor antagonists: e

20090088424 - Methods and compositions for controlling the bioavailability of poorly soluble drugs: Provided are methods and compositions for controlling the bioavailability of poorly soluble drugs, including, for example, efravirenz.... Agent: Kenyon & Kenyon LLP

20090088426 - Substituted 4-phenyl piperidines for use as renin inhibitors: Compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which R1 is straight-chain C1-8-alkanoyloxy, straight-chain C1-8-alkoxy, straight-chain C1-8-alkoxy-straight-chain-C1-8-alkoxy, straight-chain C1-8-alkoxycarbonylamino, straight-chain C0-8-alkylcarbonylamino, optionally N-mono- or N,N-di-C1-8-alkylated amino or hydroxy or straight-chain omega-hydroxy-C1-8-alkyl.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090088427 - Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors: The disclosure provides methods and compositions for treating a vascular, autoimmune, and/or inflammatory disease, or a condition associated therewith, with a dose of an inosine monophosphate dehydrogenase (IMPDH) inhibitor effective to treat the vascular, autoimmune and/or inflammatory disease, or associated condition but that does not produce immunosuppression sufficient to reduce... Agent: Dechert LLP

20090088428 - Cyclohexylimidiazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention discloses novel compounds of Formula I: (I) having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes,... Agent: Eli Lilly & Company

20090088429 - Isoquinoline derivatives: e

20090088430 - Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated... Agent: Eli Lilly & Company

20090088435 - Methods and compounds for treating retinol-related diseases: Compounds that reduce serum retinol levels are used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods, compounds, and compositions to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such... Agent: Wilson Sonsini Goodrich & Rosati

20090088436 - P38 kinase inhibiting agents: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other... Agent: Merck And Co., Inc

20090088439 - Diazinane compounds: wherein R1, R2, R3 and R4 are as defined, having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal... Agent: White & Case LLP Patent Department

20090088437 - Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles,... Agent: Millen, White, Zelano & Branigan, P.C.

20090088438 - New tyrosine derivatives as ppary modulators: and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)-B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed herein. These compounds are PPARγ modulators and, therefore, are useful for the treatment or prevention of a condition or a... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090088440 - Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics: d

20090088441 - Quinoline compounds: having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of... Agent: White & Case LLP Patent Department

20090088442 - Prophylactic/therapeutic agent for abnormalities of sugar/lipid metabolism: The present invention provides a pharmaceutical agent for the treatment and/or prophylaxis of abnormal blood glucose and lipid metabolism associated with eating, for which a sufficient treatment method or a therapeutic drug has not been found.... Agent: Leydig Voit & Mayer, Ltd

20090088443 - Novel crystalline forms of conazoles and methods of making and using the same: The invention provides novel soluble conazole crystalline forms (e.g. itraconazole, posaconazole and saperconazole) that include salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic... Agent: Philip S. Johnson Johnson & Johnson

20090088445 - Deazapurines useful as inhibitors of janus kinases: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Inc.

20090088446 - Purinone derivatives as hm74a agonists: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.... Agent: Pepper Hamilton LLP

20090088447 - Solid forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use: Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate and salts thereof are disclosed.... Agent: Lexicon Pharmaceuticals, Inc.

20090088448 - Rapamycin derivatives and the uses thereof in the treatment of neurological disorders: Provided is a method of treating neurodegenerative disorders comprising administering to a subject in need thereof a compound of formula I:... Agent: Wyeth Patent Law Group

20090088449 - 4-acylaminopyridine derivative mediated neurogenesis: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes methods based on use of a 4-acylaminopyridine derivative to stimulate or activate the formation of new nerve cells.... Agent: Leydig Voit & Mayer, Ltd

20090088454 - Anti-cancer compounds: The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers.... Agent: Sheridan Ross PC

20090088455 - Chronic, bolus adminstration of d-threo methylphenidate: Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and... Agent: Woodcock Washburn LLP

20090088456 - 2-pyridinylethylcarboxamide derivatives and their use as fugicides: r

20090088457 - Primary amines as renin inhibitors: The invention relates to novel primary amine derivatives and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors... Agent: Hoxie & Associates LLC

20090088459 - Novel biaryl sulfonamide derivatives: m

20090088461 - Methods of treating or preventing cardiac disease associated with a high fat diet: The present invention relates to a method of treating or preventing cardiac disorders, myocardial inflammation or myocardial oxidative stress associated with a high fat diet or in a patient subjected to a high fat diet using the thiazolium compounds and compositions of the invention. The present invention also relates to... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090088462 - Pharmaceutical composition for enhancing adiponectin production: Method for treatment of a human patient having hypoadiponectinemia. 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically salt thereof is administered in an amount effective to raise the level of adiponectine in said patient.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090088463 - Pyrazoles useful in the treatment of inflammation: There is provided compounds of formula (I), wherein X1 to X5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment... Agent: Morgan Lewis & Bockius LLP

20090088472 - Protective agent for neuronal cell comprising amidino derivative as active ingredient: An object of the present invention is to provide a protective agent for a neuronal cell. The protective agent for a neuronal cell according to the present invention contains a compound represented by the following general formula [I] or a salt thereof as an active ingredient. In the formula, R1,... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090088473 - Method for screening of prostaglandin compounds comprising an optimal formulation for the enhancement of hair growth and the stimulation of follicular anagen and formulations resulting therefrom: A method for developing Prostaglandin F2α analogs for enhancing and sustaining the growth of eye lashes. The exemplary method first provides a method for determining the ability of a FP receptor agonist test compound having unknown hair growth ability to induce hair growth in its free acid form. The test... Agent: Reising, Ethington, Barnes, Kisselle, P.C.

20090088474 - Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome: m

20090088475 - Indanone derivatives that inhibit prolyl hydroxylase:

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140410: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.40012 seconds

PATENT INFO